WO2019044947A1 - 抗体-薬物コンジュゲートの改良製造方法 - Google Patents
抗体-薬物コンジュゲートの改良製造方法 Download PDFInfo
- Publication number
- WO2019044947A1 WO2019044947A1 PCT/JP2018/032056 JP2018032056W WO2019044947A1 WO 2019044947 A1 WO2019044947 A1 WO 2019044947A1 JP 2018032056 W JP2018032056 W JP 2018032056W WO 2019044947 A1 WO2019044947 A1 WO 2019044947A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound represented
- converting
- antibody
- compound
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to an improved method for producing a drug-linker intermediate of an antibody-drug conjugate, and an improved method for producing an antibody-drug conjugate using the same.
- An antibody-drug conjugate in which a cytotoxic drug is bound to an antibody that binds to an antigen that is expressed on the surface of cancer cells and that can be internalized in cells is selected for cancer cells. It is expected that the drug can be delivered to accumulate the drug in the cancer cells and kill the cancer cells (Non-Patent Documents 1 to 5).
- antibody-drug conjugates having an antibody and a topoisomerase I inhibitor, exatecan, as its components (patent documents 1 to 5, non-patent documents 6 and 7) are known. Because these antibody-drug conjugates have excellent antitumor effects and safety, clinical trials are currently underway.
- the drug linker intermediate for producing the antibody-drug conjugate of the present invention has the formula (1)
- Patent Documents 1 to 4 As methods for producing the compound represented by the formula (1), methods described in Patent Documents 1 to 4 are known. However, it is not known that the compound represented by the formula (1) can be obtained as a crystal, and it is necessary to carry out complicated operations such as purification by chromatography, so it is industrially superior. Development of a manufacturing method is desired.
- the inventors of the present invention have found that the compound represented by the formula (1) can be obtained as crystals astonishingly as a result of intensive studies on a method for producing a drug linker intermediate. Moreover, as a result of improving the manufacturing method of the compound represented by Formula (1), the industrially superior manufacturing method which did not require refinement
- a crystal of the compound represented by the formula (1) including the step of preparing a solution in which the compound represented by the formula is dissolved, and then precipitating crystals of the compound represented by the formula (1) from the solution Manufacturing method.
- the crystal of the compound represented by the formula (1) has a powder X-ray diffraction obtained by irradiation with copper K ⁇ rays: 5.6 ⁇ 0.2 °, 15.5 ⁇ 0.2 °, and 22.0
- the production method according to [3] which shows a main peak at a diffraction angle (2 ⁇ ) of ⁇ 0.2 °.
- the step of reacting the compound represented by the formula (J) with the compound represented by the formula (K) to convert into a compound represented by the formula (L) is carried out in the presence of an aqueous sodium hydroxide solution [ [23] or [24].
- the step of reacting the compound represented by the formula (J) with the compound represented by the formula (K) to convert the compound into a compound represented by the formula (L) comprises the steps of: row in the presence of tris (pentafluorophenyl) borane
- acid is added to form a compound represented by Formula (M)
- the step of converting a compound represented by the formula (10) into a compound represented by the formula (1) by condensing the compound represented by the formula (10) is a two-phase system of sodium sulfate aqueous solution and tetrahydrofuran
- R 3 is an amino group protected by a (9H-fluoren-9-ylmethoxy) carbonyl group.
- R 2 is a carboxy group protected with a benzyl group.
- R 3 is an amino group protected by a (9H-fluoren-9-ylmethoxy) carbonyl group.
- the manufacturing method of the compound represented by Formula (1) including the process converted into the compound represented by these.
- the production method according to [67], wherein the compound represented by the formula (11) is a methanesulfonic acid salt anhydride.
- the production method according to [67], wherein the compound represented by the formula (11) is methanesulfonate monohydrate.
- a method for producing an antibody-drug conjugate in which a drug linker represented by and an antibody are linked by a thioether bond [80] The production method according to [79], wherein the antibody is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, or an anti-GPR20 antibody. [81] The method according to [80], wherein the antibody is an anti-HER2 antibody. [82] Or an antibody comprising an anti-HER2 antibody comprising a heavy chain consisting of the amino acid sequence as set forth in amino acid Nos. 1-449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence as set forth in amino acid nos.
- An antibody wherein the anti-HER3 antibody comprises a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 4
- the present invention it is possible to obtain crystals of the compound represented by the formula (1), and to provide a compound represented by the formula (1) of a fixed quality. Moreover, the manufacturing method of the compound represented by Formula (1) which is industrially excellent which does not require the purification
- Amino acid sequence of anti-HER2 antibody heavy chain (SEQ ID NO: 1).
- Amino acid sequence of anti-HER2 antibody light chain (SEQ ID NO: 2).
- 1 shows powder X-ray diffraction of crystals of 1,2-dimethoxyethane adduct of a compound represented by formula (10).
- 1 shows powder X-ray diffraction of crystals of a compound represented by formula (1).
- Amino acid sequence of anti-HER3 antibody heavy chain SEQ ID NO: 3
- FIG. 7 shows the amino acid sequence of anti-HER3 antibody light chain (SEQ ID NO: 4).
- FIG. 7 shows the amino acid sequence of the anti-TROP2 antibody heavy chain (SEQ ID NO: 5).
- FIG. 7 shows the amino acid sequence of the anti-TROP2 antibody light chain (SEQ ID NO: 6). Amino acid sequence of anti-B7-H3 antibody heavy chain (SEQ ID NO: 7). Amino acid sequence of anti-B7-H3 antibody light chain (SEQ ID NO: 8).
- FIG. 10 shows the amino acid sequence of anti-GPR20 antibody heavy chain (SEQ ID NO: 9).
- FIG. 10 shows the amino acid sequence of anti-GPR20 antibody light chain (SEQ ID NO: 10).
- Antibody-drug conjugate The antibody-drug conjugates produced according to the invention are Formula (19)
- A represents the binding position with the antibody
- an antibody-drug conjugate in which an antibody is linked via a thioether bond
- a partial structure consisting of a linker and a drug is referred to as a "drug linker”.
- This drug linker is a thiol group (in other words, the sulfur atom of a cysteine residue) generated at the disulfide bond site (between two heavy chains-heavy chain and between two heavy chains-light chain) of the antibody chain.
- the drug linker of the present invention is composed of exatecan which is a topoisomerase I inhibitor.
- Ekatekan is Formula (11)
- camptothecin derivative having an antitumor effect, as shown in
- the antibody-drug conjugate used in the present invention is Formula (20)
- n is the same as the so-called average drug binding number (DAR; Drug-to-Antibody Ratio), and indicates the average binding number of drug linkers per antibody.
- DAR Drug-to-Antibody Ratio
- the antibody-drug conjugate used in the present invention is expressed by Formula (22) after being transferred into cancer cells.
- the compound represented by the formula (22) is considered to be the main anti-tumor activity of the antibody-drug conjugate produced according to the present invention, and has been confirmed to have topoisomerase I inhibitory activity (Ogitani Y. et al. et al., Clinical Cancer Research, 2016, Oct 15; 22 (20): 5097-5108, Epub 2016 Mar 29).
- the compound represented by the formula (22) is considered to be generated by cleavage of the linker moiety of the antibody-drug conjugate produced by the present invention, Formula (21)
- the antibody-drug conjugates prepared according to the present invention are also known to possess a bystander effect (Ogitani Y. et al., Cancer Science (2016) 107, 1039-1046).
- the bystander effect is that the compound represented by the formula (22) released after the antibody-drug conjugate produced according to the present invention is internalized in target-expressing cancer cells does not express the target It is also exerted by exerting an antitumor effect on nearby cancer cells.
- Drug Linker Intermediates Used in the Preparation of Antibody-Drug Conjugates are: Formula (1)
- the compound represented by the formula (1) can be obtained as a crystal, and the crystal can be suitably used for the production of the antibody-drug conjugate of the present invention.
- the quality of the crystals of the compound represented by the formula (1) can be evaluated, for example, using the content of impurities, the amount of residual solvent, the appearance, etc. as an index.
- storage under an environment such as 25 ° C./60% RH or 40 ° C./75% RH for 3 months, 6 months, 12 months, 24 months, and 36 months Stability can be evaluated as an indicator.
- crystals of the compound represented by Formula (1) are precipitated by precipitating crystals of the compound represented by Formula (1) from a solution in which the compound represented by Formula (1) is dissolved. Manufacturing. Thereby, crystals of the compound represented by the formula (1) having high purity and constant quality can be produced.
- the crystal of the compound represented by the formula (1) preferably has diffraction angles of 5.6 °, 15.5 °, and 22.0 ° in powder X-ray diffraction obtained by irradiation of copper K ⁇ rays. It is characterized by showing a main peak at (2 ⁇ ).
- the value of the above-mentioned diffraction angle also includes a value within the range of ⁇ 0.2 ° It is necessary to be understood (For technical common sense of measurement and evaluation by powder X-ray diffraction, for example, the 16th revised Japanese Pharmacopoeia p64-68 (2.58 powder X-ray diffraction measurement method), or the 17th revised Japanese pharmacy, P. 71-74 (2.58 powder X-ray diffraction measurement method) etc. can be referred to).
- ⁇ 0.2 ° indicates a value within the range of ⁇ 0.2 ° to + 0.2 ° for a specific numerical value.
- “5.6 ⁇ 0.2 °” indicates a numerical value in the range of 5.4 ° to 5.8 °.
- the solution for precipitating the crystals of the compound represented by the formula (1) is preferably a solution containing acetone and a lower alcohol as a solvent.
- a solution containing a lower ketone and a lower alcohol as a solvent can also be suitably used as a solution for precipitating crystals of the compound represented by the formula (1).
- lower ketone refers to ketones having 3 to 6 carbon atoms, and examples thereof include acetone, methyl ethyl ketone, methyl propyl ketone, methyl isopropyl ketone, methyl butyl ketone, methyl isobutyl ketone, methyl tert-butyl ketone And ethyl ethyl ketone, ethyl propyl ketone, and ethyl isopropyl ketone, preferably acetone and methyl ethyl ketone, and more preferably acetone.
- lower alcohol refers to alcohols having 1 to 4 carbon atoms, and examples thereof include methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-methyl-1-propanol, Examples include 2-butanol and tert-butanol, preferably 1-propanol and 2-butanol, and more preferably 1-propanol.
- the solution for precipitating the crystals of the compound represented by the formula (1) is preferably a solution containing acetone and 1-propanol or a solution containing acetone and 2-butanol, more preferably Is a solution containing acetone and 1-propanol.
- Precipitation of crystals of the compound represented by the formula (1) is carried out by adding seed crystals of crystals of the compound represented by the formula (1) to a solution containing the compound represented by the formula (1) It can also be done.
- the seed crystals of the crystals of the compound represented by the formula (1) can be obtained by directly carrying out the above method, but preferably, a small amount of the compound represented by the formula (1) is subjected to chromatography. After purification, it can be obtained by dissolving it in a solvent containing acetone and 1-propanol or a solvent containing acetone and 2-butanol and crystallizing it from the solution.
- the compounds represented by the formula (1) are produced with reference to the descriptions of WO 2014/057687, WO 2015/098099, WO 2015/115091, WO 2015/155998, etc. Although it is possible, preferably, those produced by the following production methods (I), (II), (III), (V), (VI) and (IX) can be used. Thereby, crystals of the compound represented by the formula (1) can be produced in high yield without using chromatography in all steps.
- Production method (I) is a method of converting a compound represented by formula (B) into a compound represented by formula (1) through steps 1 to 3. Hereinafter, steps 1 to 3 will be described in detail.
- R 1 represents an amino group protected by a protecting group, preferably represents an amino group protected by a benzyloxycarbonyl group
- R 2 represents a carboxy group protected by a protecting group, preferably In the following, represents a carboxy group protected by a benzyl group
- X represents an active ester group or a carboxy group, and preferably represents a (2,5-dioxopyrrolidin-1-yl) oxycarbonyl group.
- Process 1 This process is a process of converting into a compound represented by Formula (8) by deprotecting the protecting group of the amino group and carboxy group of the compound represented by Formula (B).
- Deprotection of the protecting group of the amino group and carboxy group of the compound represented by the formula (B) can be carried out by methods known to those skilled in the art (for example, Peter G. M. Wuts, Theodora W. Greene, Greene's Protective Groups in Organic Synthesis 4th Edition (2007), Wiley-Interscience, etc.).
- R 1 is an amino group protected by a benzyloxycarbonyl group and R 2 is a carboxy group protected by a benzyl group
- this step can be suitably carried out by the following method.
- Deprotection of the protecting group of the amino group and carboxy group of the compound represented by the formula (B) is not limited as long as the reaction proceeds, but preferably, under a hydrogen atmosphere, a palladium catalyst, a platinum catalyst, a nickel catalyst It can be carried out using a ruthenium catalyst or a rhodium catalyst, more preferably it can be carried out using a palladium catalyst, still more preferably it can be carried out using palladium carbon, and even more preferably Can use 5% palladium carbon.
- the amount of 5% palladium carbon used in this step is not limited as long as the reaction proceeds, but is preferably 5 to 40% by weight based on the compound represented by formula (B).
- the solvent used in this step is not particularly limited as long as it does not inhibit the reaction, and examples thereof include acetonitrile, dichloromethane, chloroform, methanol, ethanol, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran, 2-methyl Tetrahydrofuran, 1,4-dioxane, ethyl acetate, hexane, pentane, heptane, cyclohexane, ethylcyclohexane, benzene, toluene, chlorobenzene, acetone, 2-butanone, N, N-dimethylformamide, N, N-dimethylacetamide, 1- Mention may be made of methyl-2-pyrrolidone, dimethyl sulfoxide and water, and mixed solvents thereof, preferably a mixed solvent of tetrahydrofuran and water.
- the reaction temperature of this step is not limited as long as the reaction proceeds, but is preferably 10 to 40 ° C.
- the reaction time of this step is not limited as long as the reaction proceeds, but is preferably 1 to 5 hours.
- Step 2 is a step of converting the compound represented by the formula (8) and the compound represented by the formula (C) into a compound represented by the formula (10).
- the compound represented by the formula (C) can be a commercially available product, or one produced by a known method, or one produced by a method according to the following production method (VII).
- VII production method
- X is a (2,5-dioxopyrrolidin-1-yl) oxycarbonyl group
- this step can be suitably performed by the following method.
- the amount of the compound represented by the formula (C) used in this step is not limited as long as the reaction proceeds, but is preferably 1 to 4 equivalents relative to the compound represented by the formula (8) .
- a base is preferably used in this step.
- the base used in this step is not particularly limited as long as the reaction proceeds, and examples thereof include triethylamine, tributylamine, diisopropylethylamine, N-methylmorpholine, N-methylpyrrolidine, and N-methylpiperidine.
- N, N-diisopropylethylamine can be mentioned.
- the amount of N, N-diisopropylethylamine used in this step is not limited as long as the reaction proceeds, but is preferably 0.5 to 2 equivalents relative to the compound represented by formula (8).
- the solvent used in this step is not particularly limited as long as it does not inhibit the reaction, and examples thereof include acetonitrile, dichloromethane, chloroform, methanol, ethanol, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran, 2-methyl Tetrahydrofuran, 1,4-dioxane, ethyl acetate, hexane, pentane, heptane, cyclohexane, ethylcyclohexane, benzene, toluene, chlorobenzene, acetone, 2-butanone, N, N-dimethylformamide, N, N-dimethylacetamide, 1- Mention may be made of methyl-2-pyrrolidone, dimethyl sulfoxide and water, and mixed solvents thereof, and preferably a mixed solvent of acetonitrile and water.
- the reaction temperature of this step is not limited as long as the reaction proceeds, but is preferably 10 to 40 ° C.
- the reaction time of this step is not limited as long as the reaction proceeds, but is preferably 7 to 30 hours.
- the compound represented by the formula (10) can be suitably obtained as a crystal of 1,2-dimethoxyethane adduct.
- the quality of the crystals of the 1,2-dimethoxyethane adduct of the compound represented by the formula (10) can be evaluated, for example, using the content of impurities, the amount of residual solvent, the appearance, etc. as an index.
- storage under an environment such as 25 ° C./60% RH or 40 ° C./75% RH for 3 months, 6 months, 12 months, 24 months, and 36 months Stability can be evaluated as an indicator.
- These quality evaluations can also confirm superiority over the amorphous compound represented by Formula (10).
- the crystals of the 1,2-dimethoxyethane adduct of the compound represented by the formula (10) are preferably 19.0 ° and 25.0 ° in powder X-ray diffraction obtained by irradiation with copper K ⁇ rays. It is characterized in that it shows a main peak at the diffraction angle (2 ⁇ ) of °.
- the value of the above-mentioned diffraction angle also includes a value within the range of ⁇ 0.2 ° It is necessary to be understood (For technical common sense of measurement and evaluation by powder X-ray diffraction, for example, the 16th revised Japanese Pharmacopoeia p64-68 (2.58 powder X-ray diffraction measurement method), or the 17th revised Japanese pharmacy, P. 71-74 (2.58 powder X-ray diffraction measurement method) etc. can be referred to).
- Step 3 is a step of converting the compound represented by the formula (10) and the compound represented by the formula (11) into a compound represented by the formula (1).
- the compound represented by the formula (11) can be suitably used as a methanesulfonate, and more preferably a methanesulfonate m hydrate (wherein m is 0 to 3) And more preferably methanesulfonic acid salt anhydride, methanesulfonic acid salt monohydrate, methanesulfonic acid salt dihydrate, or methanesulfonic acid salt trihydrate It can be used as a substance, and more preferably, it can be used as a methanesulfonic acid dihydrate, but any of them can be used in the production method of the present invention.
- the above-mentioned number of hydrates can be controlled by adjusting the humidity at the time of crystal acquisition and drying.
- the amount of the compound represented by the formula (11) used in this step is not limited as long as the reaction proceeds, but preferably, it is 0.5 to 2 equivalents relative to the compound represented by the formula (10) It is.
- the compound represented by the formula (10) can be condensed with the compound represented by the formula (11) suitably by derivatization to an active ester.
- Derivation to an active ester in this step is not limited as long as the reaction proceeds, for example, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (WSCD.HCl), or N, N 1-hydroxybenzotriazole (HOBt), 1-hydroxy-7-azabenzotriazole (HOAt), N-hydroxysuccinimide, ethyl cyano (hydroxyimino) acetate, using a condensing agent such as' -dicyclohexylcarbodiimide (DCC) Or by reacting with an additive such as p-nitrophenol, preferably using 3- (3-dimethylaminopropyl) carbodiimide ⁇ hydrochloride and ethyl cyano (hydroxyimino) acetate it can.
- the amount of 3- (3-dimethylaminopropyl) carbodiimide ⁇ hydrochloride used in this step is not limited as long as the reaction proceeds, but it is preferably 0. 0 to the compound represented by the formula (10). 5 to 2 equivalents.
- the amount of ethyl cyano (hydroxyimino) acetate used in this step is not limited as long as the reaction proceeds, but preferably, it is 0.02 to 0.2 equivalents relative to the compound represented by formula (10) It is.
- a base is used in this step.
- the base used in this step is not particularly limited as long as the reaction proceeds, and examples thereof include triethylamine, tributylamine, diisopropylethylamine, N-methylmorpholine, N-methylpyrrolidine, and N-methylpiperidine.
- N-methyl morpholine can be mentioned.
- the amount of N-methylmorpholine used in this step is not limited as long as the reaction proceeds, but is preferably 0.5 to 2 equivalents relative to the compound represented by formula (10).
- the solvent used in this step is not particularly limited as long as it does not inhibit the reaction, and examples thereof include acetonitrile, dichloromethane, chloroform, methanol, ethanol, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran, 2-methyl Tetrahydrofuran, 1,4-dioxane, ethyl acetate, hexane, pentane, heptane, cyclohexane, ethylcyclohexane, benzene, toluene, chlorobenzene, acetone, 2-butanone, N, N-dimethylformamide, N, N-dimethylacetamide, 1- Mention may be made of methyl-2-pyrrolidone, dimethyl sulfoxide and water, and mixed solvents thereof, preferably a mixed solvent of tetrahydrofuran and water.
- the methanesulfonic acid salt of the compound represented by the formula (11) is neutralized with a base and the reaction proceeds after becoming free.
- the methanesulfonic acid salt of the compound represented by the formula (11) is hydrophilic, while the free form of the compound represented by the formula (11) is lipophilic, so the series of reactions is efficient
- this process can be suitably carried out in a two-phase system of an aqueous layer and an organic layer.
- an aqueous solution having high ionic strength for example, an aqueous solution of sodium sulfate can be suitably used as the aqueous layer which is not miscible with it.
- the reaction temperature of this step is not limited as long as the reaction proceeds, but is preferably 10 to 40 ° C.
- the reaction time of this step is not limited as long as the reaction proceeds, but is preferably 0.5 to 2 hours.
- Production method (II) is a method of converting a compound represented by formula (B) to a compound represented by formula (1) through steps 4 to 7. Hereinafter, steps 4 to 7 will be described in detail.
- R 1 represents an amino group protected by a protecting group
- R 2 represents a carboxy group protected by a protecting group
- X represents an active ester group or a carboxy group, and preferably , 5-dioxopyrrolidin-1-yl) oxycarbonyl group is shown.
- Process 4 This step is a step of converting into a compound represented by formula (D) by deprotecting the protecting group of the amino group of the compound represented by formula (B).
- Deprotection of the protecting group of the amino group of the compound represented by formula (B) can be carried out by methods known to those skilled in the art (for example, Peter G. M. Wuts, Theodora W. Greene, Greene's Protective Groups in See Organic Synthesis 4th Edition (2007), Wiley-Interscience, etc.).
- Step 5 This step is a step of converting a compound represented by the formula (D) and a compound represented by the formula (C) into a compound represented by the formula (E).
- This step can be performed by the same method as step 2 of production method (I).
- Step 6 This process is a process of converting into the compound represented by Formula (10) by deprotecting the protecting group of the carboxy group of the compound represented by Formula (E).
- Deprotection of the protecting group of the carboxy group of the compound represented by the formula (B) can be carried out by methods known to those skilled in the art (for example, Peter G. M. Wuts, Theodora W. Greene, Greene's Protective Groups in See Organic Synthesis 4th Edition (2007), Wiley-Interscience, etc.).
- the compound represented by the formula (10) can be suitably obtained as a crystal of 1,2-dimethoxyethane adduct by the same method as step 2 of production method (I).
- Step 7 This step is a step of converting the compound represented by the formula (10) and the compound represented by the formula (11) into a compound represented by the formula (1).
- This step can be performed by the same method as step 3 of production method (I).
- Production method (III) is a method of converting a compound represented by formula (B) to a compound represented by formula (1) through steps 8 to 11. Hereinafter, steps 8 to 11 will be described in detail.
- R 1 represents an amino group protected by a protecting group, preferably represents an amino group protected by a (9H-fluoren-9-ylmethoxy) carbonyl group
- R 2 is protected by a protecting group A carboxy group, preferably a carboxy group protected by a benzyl group
- X represents an active ester group or a carboxy group, preferably (2,5-dioxopyrrolidin-1-yl). Indicates an oxycarbonyl group.
- Step 8 This process is a process of converting into a compound represented by Formula (F) by deprotecting the protecting group of the carboxy group of the compound represented by Formula (B).
- Deprotection of the protecting group of the carboxy group of the compound represented by the formula (B) can be carried out by methods known to those skilled in the art (for example, Peter G. M. Wuts, Theodora W. Greene, Greene's Protective Groups in See Organic Synthesis 4th Edition (2007), Wiley-Interscience, etc.).
- R 2 is a carboxy group protected by a benzyl group
- this step can be suitably performed by the following method.
- Deprotection of the protecting group of the carboxy group of the compound represented by the formula (B) is not limited as long as the reaction proceeds, but preferably, under a hydrogen atmosphere, a palladium catalyst, a platinum catalyst, a nickel catalyst, a ruthenium catalyst It can be carried out using a rhodium catalyst, more preferably it can be carried out using a palladium catalyst, still more preferably it can be carried out using palladium carbon, still more preferably palladium carbon Ethylenediamine complexes can be used.
- the amount of palladium carbon-ethylenediamine complex used in this step is not limited as long as the reaction proceeds, but is preferably 34 to 136% by weight based on the compound represented by formula (B).
- the solvent used in this step is not particularly limited as long as it does not inhibit the reaction, and examples thereof include acetonitrile, dichloromethane, chloroform, methanol, ethanol, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran, 2-methyl Tetrahydrofuran, 1,4-dioxane, ethyl acetate, hexane, pentane, heptane, cyclohexane, ethylcyclohexane, benzene, toluene, chlorobenzene, acetone, 2-butanone, N, N-dimethylformamide, N, N-dimethylacetamide, 1- Mention may be made of methyl-2-pyrrolidone, dimethyl sulfoxide and water, and mixed solvents thereof, preferably a mixed solvent of tetrahydrofuran and water.
- the reaction temperature of this step is preferably 10 to 40 ° C., but is not limited thereto as long as the reaction proceeds.
- the reaction time of this step is preferably 1 to 54 hours, but is not limited as long as the reaction proceeds.
- Process 9 This process is a process of converting into a compound represented by Formula (G) by condensing a compound represented by Formula (F) and a compound represented by Formula (11).
- the compound represented by the formula (F) can be condensed with the compound represented by the formula (11) suitably by derivatization to an active ester.
- the amount of the compound represented by the formula (11) used in this step is not limited as long as the reaction proceeds, but preferably, the compound represented by the formula (F) is 0.7 to 1. 3 equivalents.
- Derivation to an active ester in this step is not limited as long as the reaction proceeds, for example, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (WSCD.HCl), or N, N 1-hydroxybenzotriazole (HOBt), 1-hydroxy-7-azabenzotriazole (HOAt), N-hydroxysuccinimide, ethyl cyano (hydroxyimino) acetate, using a condensing agent such as' -dicyclohexylcarbodiimide (DCC) Alternatively, it can be carried out by reacting with an additive such as p-nitrophenol, preferably using 3- (3-dimethylaminopropyl) carbodiimide ⁇ hydrochloride and 1-hydroxybenzotriazole.
- an additive such as p-nitrophenol
- the amount of 3- (3-dimethylaminopropyl) carbodiimide hydrochloride used in this step is not limited as long as the reaction proceeds, but preferably, the amount of the compound represented by the formula (F) is preferably 0. 7 to 1.3 equivalents.
- the amount of 1-hydroxybenzotriazole used in this step is not limited as long as the reaction proceeds, but is preferably 0.7 to 1.3 equivalents relative to the compound represented by formula (F) .
- a base is used in this step.
- the base used in this step is not particularly limited as long as the reaction proceeds, and examples thereof include triethylamine, tributylamine, diisopropylethylamine, N-methylmorpholine, N-methylpyrrolidine, and N-methylpiperidine.
- a triethylamine can be mentioned.
- the amount of triethylamine used in this step is not limited as long as the reaction proceeds, but is preferably 0.7 to 1.3 equivalents relative to the compound represented by formula (F).
- the solvent used in this step is not particularly limited as long as it does not inhibit the reaction, and examples thereof include acetonitrile, dichloromethane, chloroform, methanol, ethanol, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran, 2-methyl Tetrahydrofuran, 1,4-dioxane, ethyl acetate, hexane, pentane, heptane, cyclohexane, ethylcyclohexane, benzene, toluene, chlorobenzene, acetone, 2-butanone, N, N-dimethylformamide, N, N-dimethylacetamide, 1- Mention may be made of methyl-2-pyrrolidone, dimethyl sulfoxide and water, and mixed solvents thereof, preferably tetrahydrofuran.
- the reaction temperature of this step is not limited as long as the reaction proceeds, but is preferably 10 to 40 ° C.
- the reaction time of this step is not limited as long as the reaction proceeds, but is preferably 1 to 4 hours.
- Step 10 This process is a process of converting into a compound represented by Formula (16) by deprotecting the protecting group of the amino group of the compound represented by Formula (G).
- Deprotection of the protecting group of the amino group of the compound represented by formula (G) can be carried out by methods known to those skilled in the art (for example, Peter G. M. Wuts, Theodora W. Greene, Greene's Protective Groups in See Organic Synthesis 4th Edition (2007), Wiley-Interscience, etc.).
- R 1 is an amino group protected by a (9H-fluoren-9-ylmethoxy) carbonyl group
- this step can be suitably carried out by the following method.
- Deprotection of the protecting group of the amino group of the compound represented by the formula (G) is not particularly limited as long as the reaction proceeds, and, for example, 1,8-diazabicyclo [5,4,0] -7-undecene, Trimethylguanidine, 1,5,7-triazabicyclo [4,4,0] dec-5-ene, or 7-methyl-1,5,7-triazabicyclo [4,4,0] deca-5- It can be carried out with ene 1,5-diazabicyclo [4,3,0] -5-nonene, preferably with 1,8-diazabicyclo [5,4,0] -7-undecene Can.
- the amount of 1,8-diazabicyclo [5,4,0] -7-undecene used in this step is not limited as long as the reaction proceeds, but preferably, to the compound represented by formula (15) 0.5 to 2 equivalents.
- the solvent used in this step is not particularly limited as long as it does not inhibit the reaction, and examples thereof include acetonitrile, dichloromethane, chloroform, methanol, ethanol, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran, 2-methyl Tetrahydrofuran, 1,4-dioxane, ethyl acetate, hexane, pentane, heptane, cyclohexane, ethylcyclohexane, benzene, toluene, chlorobenzene, acetone, 2-butanone, N, N-dimethylformamide, N, N-dimethylacetamide, 1- Mention may be made of methyl-2-pyrrolidone, dimethyl sulfoxide and water, and mixed solvents thereof, preferably tetrahydrofuran.
- the reaction temperature of this step is not limited as long as the reaction proceeds, but is preferably 10 to 40 ° C.
- the reaction time of this step is not limited as long as the reaction proceeds, but is preferably 1 to 5 hours.
- Step 11 is a step of converting the compound represented by the formula (16) and the compound represented by the formula (C) into a compound represented by the formula (1).
- the compound represented by the formula (C) can be a commercially available product, one produced by a known method, or one produced by a method according to the following production method (VII).
- VII production method
- X is a (2,5-dioxopyrrolidin-1-yl) oxycarbonyl group
- this step can be suitably performed by the following method.
- the amount of the compound represented by the formula (C) used in this step is not limited as long as the reaction proceeds, but preferably, it is 0.5 to 2 equivalents relative to the compound represented by the formula (16) It is.
- a base is used in this step.
- the base used in this step is not particularly limited as long as the reaction proceeds, and examples thereof include triethylamine, tributylamine, diisopropylethylamine, N-methylmorpholine, N-methylpyrrolidine, and N-methylpiperidine.
- a triethylamine can be mentioned.
- the amount of triethylamine used in this step is not limited as long as the reaction proceeds, but is preferably 0.75 to 6 equivalents with respect to the compound represented by Formula (16).
- pyridinium p-toluenesulfonate can be further used in this step.
- the amount of pyridinium p-toluenesulfonate used in this step is not limited as long as the reaction proceeds, but is preferably 1 to 4 equivalents relative to the compound represented by formula (16).
- the solvent used in this step is not particularly limited as long as it does not inhibit the reaction, and examples thereof include acetonitrile, dichloromethane, chloroform, methanol, ethanol, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran, 2-methyl Tetrahydrofuran, 1,4-dioxane, ethyl acetate, hexane, pentane, heptane, cyclohexane, ethylcyclohexane, benzene, toluene, chlorobenzene, acetone, 2-butanone, N, N-dimethylformamide, N, N-dimethylacetamide, 1- Mention may be made of methyl-2-pyrrolidone, dimethylsulfoxide, pyridine and water, and mixed solvents thereof, preferably a mixed solvent of pyridine, acetonitrile and tetrohydrofuran. It can be.
- the reaction temperature of this step is not limited as long as the reaction proceeds, but is preferably 10 to 40 ° C.
- the reaction time of this step is not limited as long as the reaction proceeds, but is preferably 1.5 to 7 hours.
- Production method (IV) is a method of converting a compound represented by formula (H) into a compound represented by formula (B) through steps 12-15. Hereinafter, steps 12 to 15 will be described in detail.
- R 1 represents an amino group protected by a protecting group, and preferably represents an amino group protected by a benzyloxycarbonyl group or (9H-fluoren-9-ylmethoxy) carbonyl group
- R 2 Represents a carboxy group protected by a protecting group, preferably a carboxy group protected by a benzyl group
- R 3 represents an amino group protected by a protecting group, preferably (9H-fluorene- 9-ylmethoxy) represents an amino group protected by a carbonyl group
- X represents an active ester group or a carboxy group, and preferably represents a (2,5-dioxopyrrolidin-1-yl) oxycarbonyl group.
- Step 12 This step is a step of converting the compound represented by the formula (H) into a compound represented by the formula (J) by reacting with lead tetraacetate.
- the compounds represented by the formula (H) commercially available ones or those prepared by referring to known methods can be used.
- the amount of lead tetraacetate used in this step is not limited as long as the reaction proceeds, but is preferably 1 to 3 equivalents relative to the compound represented by formula (H).
- This step can be suitably performed in the presence of acetic acid or pyridine, more preferably in the presence of acetic acid.
- the solvent used in this step is not particularly limited as long as it does not inhibit the reaction, and examples thereof include acetonitrile, 1,2-dimethoxyethane, tetrahydrofuran, 2-methyltetrahydrofuran, 1,4-dioxane, ethyl acetate, Mention may be made of N, N-dimethylformamide, N, N-dimethylacetamide, 1-methyl-2-pyrrolidone, and dimethyl sulfoxide, and mixed solvents thereof, with preference given to tetrahydrofuran.
- the reaction temperature in this step is not limited as long as the reaction proceeds, but is preferably 45 to 85 ° C., more preferably a temperature at which heating under reflux of tetrahydrofuran is performed.
- the reaction time of this step is not limited as long as the reaction proceeds, but is preferably 0.5 to 3 hours.
- Step 13 A step of converting a compound represented by the formula (J) into a compound represented by the formula (L) by reacting the compound represented by the formula (J) with a compound represented by the formula (K) in the presence of an acid or a base It is.
- the amount of the compound represented by the formula (K) used in this step is not limited as long as the reaction proceeds, but is preferably 1 to 4 equivalents relative to the compound represented by the formula (J) .
- This step can be performed in the presence of a base or an acid.
- the base used in this step is preferably an aqueous solution of sodium hydroxide.
- the amount of the aqueous sodium hydroxide solution used in this step is not limited as long as the reaction proceeds, but is preferably 0.5 to 2 equivalents relative to the compound represented by formula (J).
- the acid used in this step is preferably tris (pentafluorophenyl) borane.
- the amount of tris (pentafluorophenyl) borane used in this step is not limited as long as the reaction proceeds, but preferably, it is 0.01 to 0.1 equivalents relative to the compound represented by formula (J) It is.
- the solvent used in this step is not particularly limited as long as it does not inhibit the reaction, and examples thereof include 1,2-dimethoxyethane, tetrahydrofuran, 2-methyltetrahydrofuran and 1,4-dioxane.
- 1,2-dimethoxyethane can be mentioned.
- the reaction temperature of this step is not limited as long as the reaction proceeds, but is preferably -10 to 15 ° C.
- the reaction time of this step is not limited as long as the reaction proceeds, but is preferably 0.5 to 6 hours.
- Step 14 This step is a step of converting into a compound represented by formula (M) by deprotecting the protecting group of the amino group of the compound represented by formula (L).
- Deprotection of the protecting group of the amino group of the compound represented by formula (L) can be carried out by methods known to those skilled in the art (for example, Peter G. M. Wuts, Theodora W. Greene, Greene's Protective Groups in See Organic Synthesis 4th Edition (2007), Wiley-Interscience, etc.).
- R 3 is an amino group protected by a (9H-fluoren-9-ylmethoxy) carbonyl group
- this step can be suitably carried out in the following manner.
- Deprotection of the protecting group of the amino group of the compound represented by the formula (L) is not particularly limited as long as the reaction proceeds, and for example, 1,8-diazabicyclo [5,4,0] -7-undecene, Trimethylguanidine, 1,5,7-triazabicyclo [4,4,0] dec-5-ene, or 7-methyl-1,5,7-triazabicyclo [4,4,0] deca-5- It can be carried out with ene 1,5-diazabicyclo [4,3,0] -5-nonene, preferably with 1,8-diazabicyclo [5,4,0] -7-undecene Can.
- the amount of 1,8-diazabicyclo [5,4,0] -7-undecene used in this step is not limited as long as the reaction proceeds, but
- the solvent used in this step is not particularly limited as long as it does not inhibit the reaction, and examples thereof include acetonitrile, dichloromethane, chloroform, methanol, ethanol, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran, 2-methyl Tetrahydrofuran, 1,4-dioxane, ethyl acetate, hexane, pentane, heptane, cyclohexane, ethylcyclohexane, benzene, toluene, chlorobenzene, acetone, 2-butanone, N, N-dimethylformamide, N, N-dimethylacetamide, 1- Mention may be made of methyl-2-pyrrolidone, dimethyl sulfoxide, and water, and mixed solvents thereof, preferably acetonitrile and N, N-dimethylacetamide.
- the reaction temperature of this step is not limited as long as the reaction proceeds, but is preferably 10 to 40 ° C.
- the reaction time of this step is not limited as long as the reaction proceeds, but is preferably 2 to 8 hours.
- the compound represented by the formula (M) can be precipitated from the reaction solution by converting it into a salt with an acid, and can be preferably isolated and purified. Thereby, by-products that can be a reaction inhibiting factor in the subsequent steps can be removed.
- the above acid is preferably 1-hydroxybenzotriazole.
- the 1-hydroxybenzotriazole used in this step can also function as one of the condensing agents in the next step 15. Similarly, acids other than 1-hydroxybenzotriazole can be suitably used in this step as long as they function as one of the condensing agents.
- Step 15 is a step of converting the compound represented by Formula (M) and the compound represented by Formula (N) into a compound represented by Formula (B).
- the compound represented by the formula (N) can be a commercially available product, one produced by a known method, or one produced by a method according to the following production method (VIII).
- the amount of the compound represented by the formula (N) used in this step is not limited as long as the reaction proceeds, but preferably, the compound represented by the formula (M) is 0.7 to 1. 3 equivalents.
- the compounds of formula (M) can suitably be condensed with the compounds of formula (N) by derivatisation to the active ester.
- the derivatization to the active ester is carried out using, for example, a condensing agent such as 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide ⁇ hydrochloride (WSCD ⁇ HCl) or N, N′-dicyclohexylcarbodiimide (DCC).
- a condensing agent such as 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide ⁇ hydrochloride (WSCD ⁇ HCl) or N, N′-dicyclohexylcarbodiimide (DCC).
- this step can be suitably performed without adding new 1-hydroxybenzotriazole.
- the solvent used in this step is not particularly limited as long as it does not inhibit the reaction, and examples thereof include acetonitrile, dichloromethane, chloroform, methanol, ethanol, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran, 2-methyl Tetrahydrofuran, 1,4-dioxane, ethyl acetate, hexane, pentane, heptane, cyclohexane, ethylcyclohexane, benzene, toluene, chlorobenzene, acetone, 2-butanone, N, N-dimethylformamide, N, N-dimethylacetamide, 1- Mention may be made of methyl-2-pyrrolidone, dimethyl sulfoxide and water, and mixed solvents thereof, preferably a mixed solvent of acetonitrile and water.
- the solvent used at the process 14 can use the solvent used at the process 14 as it is.
- the reaction temperature of this step is not limited as long as the reaction proceeds, but is preferably -10 to 15 ° C.
- the reaction time of this step is not limited as long as the reaction proceeds, but is preferably 1.5 to 7 hours.
- the compound represented by Formula (1) can use suitably what was manufactured with the following manufacturing method (V) or (VI).
- the production method (V) is a method of converting the compound represented by the formula (2) into the compound represented by the formula (1) through steps 16 to 22. Steps 16 to 22 will be described in detail below.
- Step 16 This step is a step of converting a compound represented by the formula (2) into a compound represented by the formula (3) by reacting with lead tetraacetate.
- the compound represented by Formula (2) can use a commercially available thing or what was manufactured with reference to a well-known method. This step can be carried out by the same method as step 12 of production method (IV).
- Step 17 This step is a step of converting a compound represented by the formula (3) into a compound represented by the formula (4) by reacting it with benzyl glycolate in the presence of an acid or a base. This step can be carried out by the same method as step 13 of production method (IV).
- Step 18 This process is a process of converting into the compound represented by Formula (5) by deprotecting the protecting group of the amino group of the compound represented by Formula (4). This step can be carried out by the same method as step 14 of production method (IV).
- Step 19 This process is a process of converting into a compound represented by Formula (7) by condensing the compound represented by Formula (5) and the compound represented by Formula (6).
- the compound represented by the formula (6) commercially available products, those produced by known methods, or those produced by the following production method (VIII) can be used. This step can be carried out by the same method as step 15 of production method (IV).
- Process 20 This process is a process of converting into a compound represented by Formula (8) by deprotecting the protecting group of the amino group and carboxy group of the compound represented by Formula (7). This process can be performed by the method similar to the process 1 of manufacturing method (I).
- Step 21 This step is a step of converting the compound represented by the formula (8) and the compound represented by the formula (9) into a compound represented by the formula (10). This step can be performed by the same method as step 2 of production method (I).
- Step 22 is a step of converting the compound represented by the formula (10) and the compound represented by the formula (11) into a compound represented by the formula (1). This step can be performed by the same method as step 3 of production method (I).
- Production method (VI) is a method of converting a compound represented by the formula (2) into a compound represented by the formula (1) through steps 23 to 30. Hereinafter, steps 23 to 30 will be described in detail.
- Step 23 is a step of converting a compound represented by the formula (2) into a compound represented by the formula (3) by reacting with lead tetraacetate.
- the compound represented by Formula (2) can use a commercially available thing or what was manufactured with reference to a well-known method. This step can be carried out by the same method as step 12 of production method (IV).
- Step 24 is a step of converting a compound represented by the formula (3) into a compound represented by the formula (4) by reacting it with benzyl glycolate in the presence of an acid or a base. This step can be carried out by the same method as step 13 of production method (IV).
- Step 25 This process is a process of converting into the compound represented by Formula (5) by deprotecting the protecting group of the amino group of the compound represented by Formula (4). This step can be carried out by the same method as step 14 of production method (IV).
- Step 26 This step is a step of converting the compound represented by the formula (5) and the compound represented by the formula (12) into a compound represented by the formula (13).
- the compound represented by Formula (13) can use a commercially available thing or what was manufactured by the well-known method. This step can be carried out by the same method as step 15 of production method (IV).
- Step 27 This process is a process of converting into the compound represented by Formula (14) by deprotecting the protecting group of the carboxy group of the compound represented by Formula (13). This step can be carried out by the same method as step 8 of production method (III).
- Step 28 This step is a step of converting the compound represented by the formula (14) and the compound represented by the formula (11) into a compound represented by the formula (15). This step can be carried out by the same method as step 9 of production method (III).
- Step 29 This process is a process of converting into a compound represented by Formula (16) by deprotecting the protecting group of the amino group of the compound represented by Formula (15). This step can be carried out by the same method as step 10 of production method (III).
- Step 30 is a step of converting the compound represented by the formula (16) and the compound represented by the formula (9) into a compound represented by the formula (1). This step can be carried out by the same method as step 11 of production method (III).
- Step 31 is a step of converting the compound represented by the formula (17) and maleic anhydride into a compound represented by the formula (18).
- the amount of maleic anhydride used in this step is not limited as long as the reaction proceeds, but is preferably 0.7 to 1.3 equivalents with respect to the compound represented by Formula (17).
- This step is preferably carried out in acetic acid.
- the reaction temperature in this step is not limited as long as the reaction proceeds, but is preferably 80 to 120 ° C.
- the reaction time of this step is not limited as long as the reaction proceeds, but is preferably 8 to 32 hours.
- Step 32 This step is a step of converting the compound represented by the formula (18) and N-hydroxysuccinimide into a compound represented by the formula (9).
- the amount of N-hydroxysuccinimide used in this step is not limited as long as the reaction proceeds, but is preferably 0.7 to 1.3 equivalents with respect to the compound represented by Formula (17).
- the compound represented by the formula (18) can be condensed with N-hydroxysuccinimide by derivatization to an active ester, mixed acid anhydride, or acid halide or the like, and preferably to an acid halide Can be condensed with N-hydroxysuccinimide.
- the derivation to the acid halide can preferably be carried out with thionyl chloride.
- the amount of thionyl chloride used in this step is not limited as long as the reaction proceeds, but is preferably 0.5 to 1.5 equivalents relative to the compound represented by formula (18).
- a base is preferably used in this step.
- the base used in this step is preferably 2,6-lutidine.
- the amount of 2,6-lutidine used in this step is not limited as long as the reaction proceeds, but is preferably 1 to 3 equivalents relative to the compound represented by formula (18).
- the solvent used in this step is not particularly limited as long as it does not inhibit the reaction, and examples thereof include acetonitrile, dichloromethane, chloroform, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran, 2-methyltetrahydrofuran, ethyl acetate Mention may be made of hexane, pentane, heptane, cyclohexane, ethylcyclohexane, benzene, toluene, and chlorobenzene, and mixed solvents thereof, preferably acetonitrile.
- the reaction temperature of this step is not limited as long as the reaction proceeds, but is preferably ⁇ 25 ° C. to 0 ° C.
- the reaction time of this step is not limited as long as the reaction proceeds, but is preferably 0.5 to 2 hours.
- Step 33 is a step of converting the compound represented by the formula (23) into a compound represented by the formula (24) by condensation with N-hydroxysuccinimide.
- the amount of the compound represented by the formula (23) used in this step is not limited as long as the reaction proceeds, but preferably, the amount of the compound represented by the formula (23) is 0.7 to 1. 5 equivalents.
- the compound represented by the formula (23) can be condensed with N-hydroxysuccinimide by derivatization to an active ester, mixed acid anhydride, or acid halide or the like, preferably to an active esterified product. Can be condensed with N-hydroxysuccinimide.
- Active esterification can preferably be carried out using 3- (3-dimethylaminopropyl) carbodiimide ⁇ hydrochloride.
- the amount of 3- (3-dimethylaminopropyl) carbodiimide ⁇ hydrochloride used in this step is not limited as long as the reaction proceeds, but it is preferably 0. 0 for the compound represented by formula (23). 7 to 1.5 equivalents.
- the solvent used in this step is not particularly limited as long as it does not inhibit the reaction, and examples thereof include acetonitrile, dichloromethane, chloroform, methanol, ethanol, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran, 2-methyl Tetrahydrofuran, 1,4-dioxane, ethyl acetate, hexane, pentane, heptane, cyclohexane, ethylcyclohexane, benzene, toluene, chlorobenzene, acetone, 2-butanone, N, N-dimethylformamide, N, N-dimethylacetamide, 1- Mention may be made of methyl-2-pyrrolidone, dimethyl sulfoxide and water, and mixed solvents thereof, preferably acetonitrile.
- the reaction temperature of this step is not limited as long as the reaction proceeds, but is preferably 10 to 40 ° C.
- the reaction time of this step is not limited as long as the reaction proceeds, but is preferably 2 to 8 hours.
- Step 34 is a step of converting the compound represented by the formula (24) into a compound represented by the formula (6) by condensation with L-phenylalanine.
- the amount of L-phenylalanine used in this step is not limited as long as the reaction proceeds, but is preferably 0.7 to 1.3 equivalents relative to the compound represented by formula (24).
- a base is used in this step.
- the base used in this step is not particularly limited as long as the reaction proceeds, and examples thereof include triethylamine, tributylamine, diisopropylethylamine, N-methylmorpholine, N-methylpyrrolidine, and N-methylpiperidine.
- a triethylamine can be mentioned.
- the amount of triethylamine used in this step is not limited as long as the reaction proceeds, but is preferably 0.7 to 1.3 equivalents with respect to the compound represented by formula (24).
- the solvent used in this step is not particularly limited as long as it does not inhibit the reaction, and examples thereof include acetonitrile, dichloromethane, chloroform, methanol, ethanol, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran, 2-methyl Tetrahydrofuran, 1,4-dioxane, ethyl acetate, hexane, pentane, heptane, cyclohexane, ethylcyclohexane, benzene, toluene, chlorobenzene, acetone, 2-butanone, N, N-dimethylformamide, N, N-dimethylacetamide, 1- Mention may be made of methyl-2-pyrrolidone, dimethyl sulfoxide and water, and mixed solvents thereof, and preferably a mixed solvent of acetonitrile and water.
- the reaction temperature of this step is not limited as long as the reaction proceeds, but is preferably a compound represented by formula (23).
- the reaction time of this step is not limited as long as the reaction proceeds, but is preferably 1 to 4 hours.
- R 1 represents an amino group protected by a protecting group
- R 2 represents a carboxy group protected by a protecting group
- R 3 represents an amino group protected by a protecting group
- X represents an active ester Or a carboxy group, preferably a (2,5-dioxopyrrolidin-1-yl) oxycarbonyl group.
- Step 35 is a step of converting the compound represented by the formula (H) into a compound represented by the formula (J) by reacting with lead tetraacetate.
- the compounds represented by the formula (H) commercially available ones or those prepared by referring to known methods can be used. This step can be carried out by the same method as step 12 of production method (IV).
- Step 36 In this step, the compound represented by the formula (J) is converted to the compound represented by the formula (L) by reacting the compound represented by the formula (K) in the presence of an acid or a base It is a process.
- This step can be carried out by the same method as step 13 of production method (IV).
- Step 37 This step is a step of converting into a compound represented by the formula (O) by deprotecting the protecting group of the carboxy group of the compound represented by the formula (L).
- Deprotection of the protecting group of the carboxy group of the compound represented by the formula (L) can be carried out by methods known to those skilled in the art (eg, Peter G. M. Wuts, Theodora W. Greene, Greene's Protective Groups in See Organic Synthesis 4th Edition (2007), Wiley-Interscience, etc.).
- Step 38 This step is a step of converting the compound represented by the formula (O) and the compound represented by the formula (11) into a compound represented by the formula (P).
- the compound represented by the formula (O) can be condensed with the compound represented by the formula (11) suitably by derivatization to an active ester.
- Step 39 This process is a process of converting into a compound represented by Formula (25) by deprotecting the protecting group of the amino group of the compound represented by Formula (P).
- Deprotection of the protecting group of the carboxy group of the compound represented by the formula (P) can be carried out by methods known to those skilled in the art (for example, Peter G. M. Wuts, Theodora W. Greene, Greene's Protective Groups in See Organic Synthesis 4th Edition (2007), Wiley-Interscience, etc.).
- This step is a step of converting a compound represented by the formula (25) and a compound represented by the formula (N) into a compound represented by the formula (G).
- the compound represented by the formula (N) can be condensed with the compound represented by the formula (25) suitably by derivatization to an active ester.
- Step 41 This process is a process of converting into a compound represented by Formula (16) by deprotecting the protecting group of the amino group of the compound represented by Formula (G). This step can be carried out by the same method as step 10 of production method (III).
- Step 42 This step is a step of converting the compound represented by the formula (16) and the compound represented by the formula (C) into a compound represented by the formula (1). This step can be carried out by the same method as step 11 of production method (III).
- the antibody used for producing the antibody-drug conjugate of the present invention may be derived from any species but is preferably an antibody derived from human, rat, mouse and rabbit. Where the antibody is from a species other than human, it is preferable to chimerize or humanize using well known techniques.
- the antibody of the present invention may be a polyclonal antibody or a monoclonal antibody, preferably a monoclonal antibody.
- the antibody used for producing the antibody-drug conjugate of the present invention preferably has a property of being able to target cancer cells, a property of being able to recognize cancer cells, a property of being able to bind to cancer cells, Those having a property of being internalized by being taken into a cancer cell, and / or a cell-killing activity for a cancer cell, etc. are preferable.
- the binding of the antibody to cancer cells can be confirmed using flow cytometry.
- An assay that visualizes the intracellularly incorporated antibody with a fluorescent microscope using a secondary antibody (fluorescent label) that binds to the therapeutic antibody Cell Death and Differentiation (2008) ) 15, 751-761
- Assay for measuring the amount of fluorescence incorporated into cells using a secondary antibody (fluorescent label) that binds to the therapeutic antibody Molecular Biology of the Cell Vol. 15, 5268- 5282, December 2004
- Mab-ZAP assay that when incorporated into a cell, the toxin is released to suppress cell proliferation when incorporated into a therapeutic antibody (Bio Techniques 28: 162- 165, January 2000).
- a recombinant complex protein of the catalytic domain of dipthetheria toxin and protein G can also be used.
- the anti-tumor activity of the antibody can be confirmed in vitro by measuring the cell growth inhibitory activity.
- a cancer cell line overexpressing a target protein of an antibody can be cultured, and the antibody can be added to the culture system at various concentrations to measure the inhibitory activity against foci formation, colony formation and spheroid growth.
- anti-tumor activity can be confirmed by administering an antibody to a nude mouse transplanted with a cancer cell line highly expressing a target protein and measuring changes in the cancer cells.
- the anti-tumor effect of the antibody itself is not essential since the antibody-drug conjugate is conjugated with a compound that exerts an anti-tumor effect.
- the antibody-drug conjugate is conjugated with a compound that exerts an anti-tumor effect.
- the antibody In order to exert the cytotoxicity of the antitumor compound specifically and selectively in cancer cells, it is important that the antibody has a property of being internalized and transferred into the cancer cells, which is preferable.
- the antibodies used to produce the antibody-drug conjugates of the present invention can be obtained by known means. For example, it can be obtained by immunizing an animal with a polypeptide to be an antigen, and collecting and purifying antibodies produced in vivo, using methods commonly practiced in the art.
- the origin of the antigen is not limited to human, and the animal can be immunized with an antigen derived from a nonhuman animal such as a mouse or a rat.
- antibodies that can be applied to human diseases can be selected by testing the cross-reactivity between the human antigen and the antibody that binds to the obtained heterologous antigen.
- a hybridoma can be established by fusing an antibody-producing cell producing an antibody against the antigen with a myeloma cell to obtain a monoclonal antibody.
- An antigen can be obtained by causing a host cell to produce a gene encoding an antigen protein by genetic manipulation. Specifically, a vector capable of expressing an antigen gene may be prepared, introduced into a host cell to express the gene, and the expressed antigen may be purified. Antibodies can also be obtained by using the method of immunizing an animal with an antigen-expressing cell by genetic engineering or a cell line expressing the antigen.
- the antibody used in the production of the antibody-drug conjugate of the present invention is a genetically modified antibody, such as a chimeric (chimeric) antibody, a human, which has been artificially modified for the purpose of reducing heterologous antigenicity to human etc.
- a genetically modified antibody such as a chimeric (chimeric) antibody, a human, which has been artificially modified for the purpose of reducing heterologous antigenicity to human etc.
- it is a humanized antibody, or an antibody having only the gene sequence of an antibody derived from human, that is, a human antibody.
- These antibodies can be produced using known methods.
- chimeric antibodies include antibodies in which the variable region of the antibody and the constant region are heterologous to each other, such as a chimeric antibody in which the variable region of a mouse- or rat-derived antibody is conjugated to a constant region derived from human (Proc. Natl. Acad Sci. USA, 81, 6851-6855, (1984)).
- an antibody (Nature (1986) 321, p. 522-525) in which only complementarity determining region (CDR; complementarity determining region) of a heterologous antibody is incorporated into a human-derived antibody;
- CDR complementarity determining region
- some framework amino acid residues of the heterologous antibody are also grafted to human antibodies (WO 90/07861), gene conversion mutagenesis strategy Mention may be made of antibodies which have been humanized using (US Pat. No. 5,821,337).
- human antibody an antibody prepared using a human antibody-producing mouse having a human chromosomal fragment containing heavy and light chain genes of human antibody (Tomizuka, K. et al., Nature Genetics (1997) 16, p. 133-143; Kuroiwa, Y. et. Al., Nucl. Acids Res. (1998) 26, p. 3447-3448; Yoshida, H. et. Al., Animal Cell Technology: Basic and Applied Aspects vol. p. 69-73 (Kitagawa, Y., Matsuda, T. and Iijima, S. eds.), Kluwer Academic Publishers, 1999; Tomizuka, K. et. al., Proc.
- antibodies obtained by phage display selected from human antibody libraries (Wormstone, I. M. et. Al, Investigative Ophthalmology & Visual Science. (2002) 43 (7), p. 2301-2308; Mé, S. et al. et. al., Briefings in Functional Genomics and Proteomics (2002), 1 (2), p. 189-203; Siriwardena, D. et. al., Ophthalmology (2002) 109 (3), p. See also).
- the antibodies used to produce the antibody-drug conjugates of the present invention also include modified forms of the antibodies.
- denatured body means that by which chemical or biological modification is given to the antibody based on this invention.
- Chemical modifications include chemical modifications having a bond of a chemical moiety to an amino acid backbone, a bond of a chemical moiety to an N-linked or an O-linked carbohydrate chain, and the like.
- Biologically modified forms include post-translational modifications (eg, addition of N-linked or O-linked sugar chains, N- or C-terminal processing, deamidation, isomerization of aspartic acid, oxidation of methionine, etc.
- those having a methionine residue added to the N-terminus by expression using a prokaryotic host cell are also included in the meaning of such modified products.
- modified forms of the antibody according to the present invention are useful for the improvement of antibody stability and retention in blood, reduction of antigenicity, detection or isolation of antibody or antigen, and the like.
- WO 99/54342, WO 00/61739, WO 02/31140, etc. are known as techniques for modulating antibody sugar chain modification, but are not limited thereto.
- the antibodies according to the present invention also include antibodies in which the sugar chain modification has been adjusted.
- the antibody according to the present invention also includes the modified antibody and a functional fragment of the antibody, a deleted form in which one or two amino acids are deleted at the heavy chain carboxyl terminus, and amidated Also included are such deletions (eg, a heavy chain in which a proline residue at the carboxyl terminal site is amidated).
- deletion of the carboxyl terminus of the heavy chain of the antibody according to the present invention is not limited to the above-mentioned type, as long as the antigen binding ability and effector function are maintained.
- the two heavy chains constituting the antibody according to the present invention may be any one kind of heavy chain selected from the group consisting of full length and the above-mentioned deletion product, or any two kinds thereof are combined. It may be one.
- the antibody according to the present invention preferably has a carboxyl terminal at both of two heavy chains. Those in which one amino acid residue is deleted can be mentioned.
- IgG immunoglobulin G
- IgG1, IgG2, IgG3, IgG4 immunoglobulin G
- IgG1 or IgG2 can be mentioned.
- the antibody that can be used for producing the antibody-drug conjugate of the present invention is not particularly limited, and examples thereof include anti-HER2 antibody, anti-HER3 antibody, anti-TROP2 antibody, anti-B7-H3 antibody, anti-CD3 antibody, and anti-CD30 antibody, Anti-CD33, Anti-CD37, Anti-CD56, Anti-DR98, Anti-EGFR, Anti-EPHA2, Anti-FGFR2, Anti-FGFR2, Anti-FOLR1, Anti-VEGF, and Anti-GPR20 Antibodies
- anti-HER2 antibody, anti-HER3 antibody, anti-TROP2 antibody, anti-B7-H3 antibody, and anti-GPR20 antibody can be mentioned.
- the "anti-HER2 antibody” specifically binds to HER2 (Human Epidermal Growth Factor Receptor Type 2; ErbB-2), preferably, an activity to internalize in HER2-expressing cells by binding to HER2. Shows an antibody having
- trastuzumab (trastuzumab) (US Pat. No. 5,521,337) and pertuzumab (pertuzumab) (WO 01/00245) can be mentioned, with preference given to trastuzumab .
- “trastuzumab” is a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 (FIG. 1) and the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2 (FIG. 2).
- a humanized anti-HER2 monoclonal antibody comprising a light chain comprising
- the "anti-HER3 antibody” specifically binds to HER3 (Human Epidermal Growth Factor Receptor Type 3; ErbB-3), and preferably, binds to HER3 on the cell surface of HER3-expressing cell to thereby bind to HER3.
- HER3 Human Epidermal Growth Factor Receptor Type 3; ErbB-3
- the antibody which has the activity which internalizes in an expression cell is shown.
- anti-HER3 antibody for example, patritumab (patritumab; U3-1287), U1-59 (WO 2007/077028), MM-121 (seribantumab), anti-ERBB3 antibody described in WO 2008/100624, RG Mention may be made of -7116 (lumretuzumab), and LJM- 716 (elgemtumab), preferably patrizumab and U1-59.
- the "anti-TROP2 antibody” specifically binds to TROP2 (TACSTD2: Tumor-associated calcium signal transducer 2; EGP-1), preferably internalizes in TROP2-expressing cells by binding to TROP2.
- TROP2 Tumor-associated calcium signal transducer 2; EGP-1
- Antibody having the following activity.
- anti-TROP2 antibodies examples include hTINA1-H1L1 (WO 2015/098099).
- the "anti-B7-H3 antibody” specifically binds to B7-H3 (B cell antigen # 7 homolog 3; PD-L3; CD276), preferably by binding to B7-H3.
- B7-H3 B cell antigen # 7 homolog 3; PD-L3; CD276
- An antibody having an activity of internalizing B7-H3 expressing cells is shown.
- M30-H1-L4 (WO 2014/057687) can be mentioned.
- anti-GPR20 antibody refers to an antibody that specifically binds to GPR20 (G protein-coupled receptor 20), and preferably has an activity to internalize GPR20-expressing cells by binding to GPR20.
- anti-GPR20 antibodies include h046-H4e / L7 (WO 2018/135501).
- the antibody-drug conjugate of the present invention can be produced by reacting the compound represented by the formula (1) with an antibody having a thiol group (also referred to as sulfhydryl group).
- the crystal of the compound represented by the formula (1) of the present invention can be preferably used in a reaction after being dissolved in a solvent to form a solution containing the compound represented by the formula (1).
- the solvent used in this step is not particularly limited as long as it does not inhibit the reaction, but preferably, solvents containing dimethylsulfoxide, dimethylformamide, dimethylacetamide, N-methylpyrrolidone can be used.
- a solvent containing dimethyl sulfoxide can be used.
- An antibody having a sulfhydryl group can be obtained by a method known to those skilled in the art (Hermanson, GT, Bioconjugate Techniques, pp. 56-136, pp. 454-493, Academic Press (1996)).
- a reducing agent such as tris (2-carboxyethyl) phosphine hydrochloride (TCEP) is used in an amount of 0.3 to 3 molar equivalents per inter-chain disulfide of an antibody, and a chelate such as ethylenediaminetetraacetic acid (EDTA)
- TCEP 2-carboxyethyl) phosphine hydrochloride
- EDTA ethylenediaminetetraacetic acid
- an antibody-drug conjugate in which 2 to 8 drugs are bound per antibody using 2 to 20 molar equivalents of the compound represented by the formula (1) per antibody having a sulfhydryl group. Can be manufactured.
- Calculation of the average drug binding number per antibody molecule of the produced antibody-drug conjugate is calculated, for example, by measuring the UV absorbance of the antibody-drug conjugate and its conjugation precursor at two wavelengths of 280 nm and 370 nm. (UV method) or a method (HPLC method) of quantifying and calculating each fragment obtained by treating the antibody-drug conjugate with a reducing agent by HPLC measurement.
- UV method UV absorbance of the antibody-drug conjugate and its conjugation precursor at two wavelengths of 280 nm and 370 nm.
- HPLC method a method of quantifying and calculating each fragment obtained by treating the antibody-drug conjugate with a reducing agent by HPLC measurement.
- anti-HER2 antibody-drug conjugate indicates an antibody-drug conjugate in which the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
- the anti-HER2 antibody preferably comprises a heavy chain consisting of the amino acid sequence as set forth in amino acid numbers 1-449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence as set forth in amino acid numbers 1-214 in SEQ ID NO: 2. It is an antibody or an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.
- the average number of drug linkers attached per antibody of the anti-HER2 antibody-drug conjugate produced by the present invention is preferably 2 to 8, more preferably 3 to 8, and even more preferably 7 to 8, even more preferably 7.5 to 8, and even more preferably about 8.
- the anti-HER2 antibody-drug conjugate can be produced with reference to the description of WO 2015/115091 etc using the crystal of the compound represented by the formula (1) produced by the production method of the present invention it can.
- anti-HER3 antibody-drug conjugate indicates an antibody-drug conjugate in which the antibody in the antibody-drug conjugate is an anti-HER3 antibody.
- the anti-HER3 antibody comprises an antibody comprising a heavy chain consisting of the amino acid sequence as set forth in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence as set forth in SEQ ID NO: 4 It is an antibody in which a lysine residue is deleted.
- the average number of drug linkers attached per antibody of the anti-HER3 antibody-drug conjugate produced by the present invention is preferably 2 to 8, more preferably 3 to 8, and even more preferably 7 to 8, even more preferably 7.5 to 8, and even more preferably about 8.
- the anti-HER3 antibody-drug conjugate can be produced with reference to the description of WO 2015/155998 etc using the crystal of the compound represented by the formula (1) produced by the production method of the present invention it can.
- anti-TROP2 antibody-drug conjugate refers to an antibody-drug conjugate in which the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.
- the anti-TROP2 antibody suitably comprises a heavy chain consisting of the amino acid sequence as set forth in amino acid numbers 20 to 470 in SEQ ID NO: 5 and a light chain consisting of the amino acid sequence as set forth in amino acid numbers 21 to 234 in SEQ ID NO: 6 It is an antibody or an antibody in which a lysine residue at the carboxyl terminus of the heavy chain of the antibody is deleted.
- the average number of drug linkers attached per antibody of the anti-TROP2 antibody-drug conjugate produced by the present invention is preferably 2 to 8, more preferably 3 to 5, and even more preferably 3.5 to 4.5, and even more preferably about 4.
- the anti-TROP2 antibody-drug conjugate can be produced by referring to the description of WO 2015/098099 etc using the crystal of the compound represented by the formula (1) produced by the production method of the present invention. it can.
- anti-B7-H3 antibody-drug conjugate indicates an antibody-drug conjugate in which the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.
- the anti-B7-H3 antibody preferably comprises a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 in SEQ ID NO: 7 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 in SEQ ID NO: 8 Or an antibody in which a lysine residue at the carboxyl terminus of the heavy chain of the antibody is deleted.
- the average number of drug linkers attached per antibody of the anti-B7-H3 antibody-drug conjugate produced by the present invention is preferably 2 to 8, more preferably 3 to 5, and even more preferably Are from 3.5 to 4.5, and even more preferably about 4.
- the anti-B7-H3 antibody-drug conjugate is produced with reference to the description of WO 2014/057687 etc using the crystal of the compound represented by the formula (1) produced by the production method of the present invention. be able to.
- anti-GPR20 antibody-drug conjugate indicates an antibody-drug conjugate in which the antibody in the antibody-drug conjugate is an anti-GPR20 antibody.
- the anti-GPR20 antibody comprises a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 472 in SEQ ID NO: 9 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 234 in SEQ ID NO: 10 It is an antibody or an antibody in which a lysine residue at the carboxyl terminus of the heavy chain of the antibody is deleted.
- the average number of drug linkers attached per antibody of the anti-GPR20 antibody-drug conjugate produced by the present invention is preferably 2 to 8, more preferably 3 to 8, and even more preferably 7 to 8, even more preferably 7.5 to 8, and even more preferably about 8.
- the anti-GPR20 antibody-drug conjugate can be produced by reference to the description of WO 2018/135501 etc using the crystal of the compound represented by the formula (1) produced by the production method of the present invention it can.
- the antibody-drug conjugates produced by the present invention can be administered including one or more pharmaceutically compatible components.
- the pharmaceutically compatible component is suitably selected from formulation additives and the like usually used in this field according to the dose, concentration and the like of the antibody-drug conjugate produced according to the present invention.
- the antibody-drug conjugates prepared according to the invention are administered as a pharmaceutical composition comprising a buffer such as histidine buffer, an excipient such as sucrose or trehalose, and a surfactant such as polysorbate 80 or polysorbate 20 It can be done.
- the pharmaceutical composition containing the antibody-drug conjugate produced according to the present invention can be applied to patients as a systemic therapy, as well as applied locally to cancer tissues to expect a therapeutic effect.
- the pharmaceutical composition containing the antibody-drug conjugate produced by the present invention can be suitably used for mammals, but more preferably for humans.
- the pharmaceutical composition containing the antibody-drug conjugate produced according to the present invention can suitably be used as an injection, and more preferably used as an aqueous injection or a lyophilization injection. Even more preferably, it can be used as a lyophilised injection.
- the pharmaceutical composition containing the antibody-drug conjugate produced according to the present invention is an aqueous injection, it can be suitably administered intravenously by dilution after dilution with an appropriate diluent.
- an appropriate diluent glucose solution (preferably 5% glucose solution), physiological saline, etc. can be mentioned.
- the pharmaceutical composition containing the antibody-drug conjugate produced according to the present invention is a lyophilised injection, preferably after dissolving with water for injection, the necessary amount is diluted with an appropriate dilution solution and then intravenously Can be administered by infusion.
- an appropriate dilution solution preferably glucose solution, physiological saline, etc. can be mentioned.
- Routes of introduction that can be used to administer a pharmaceutical composition comprising an antibody-drug conjugate prepared according to the invention include, for example, intravenous, intradermal, subcutaneous, intramuscular and intraperitoneal routes And preferably include intravenous routes.
- the antibody-drug conjugates produced according to the present invention can be administered to humans at intervals of once every 1 to 180 days, preferably one week, two weeks, three weeks or four weeks Can be administered at intervals of one hour, and even more preferably, once every three weeks.
- the antibody-drug conjugate produced according to the present invention can be administered at a dose of about 0.001 to 100 mg / kg per dose, preferably, 0.8 to 12.4 mg per dose. It can be administered at a dose of / kg.
- the antibody-drug conjugate prepared according to the present invention is an anti-HER2 antibody-drug conjugate, it is preferably administered at a dose of 5.4, 6.4 or 7.4 mg / kg per dose. Even more preferably, it can be administered at a dose of 5.4 mg / kg or 6.4 mg / kg per dose.
- the pharmaceutical composition comprising the antibody-drug conjugate produced according to the present invention can be used for the treatment of cancer, preferably breast cancer, stomach cancer (sometimes called gastric adenocarcinoma), large intestine Cancer (sometimes called colorectal cancer, including colon cancer and rectum cancer), lung cancer (including small cell lung cancer and non-small cell lung cancer), esophagus cancer, salivary gland cancer, gastroesophageal junction Adenocarcinoma, bile duct cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, gastrointestinal stromal tumor, Cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, colon cancer, rectal cancer, endometrial cancer, uterine cancer, renal cancer, vulval cancer, Thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma,
- compositions comprising the antibody-drug conjugates produced according to the present invention can be selected and used as medicaments for drug therapy, which is a major treatment for cancer treatment, as a result of which cancer It can slow down cell growth, reduce proliferation, and even destroy cancer cells.
- drug therapy is a major treatment for cancer treatment, as a result of which cancer It can slow down cell growth, reduce proliferation, and even destroy cancer cells.
- the pharmaceutical composition comprising the antibody-drug conjugate produced according to the present invention can also be used in combination with other therapies in adjuvant therapy, surgery It can be combined with radiation therapy, hormonal therapy, etc. Furthermore, it can also be used as a drug therapy in neoadjuvant therapy.
- the pharmaceutical composition containing the antibody-drug conjugate produced according to the present invention is also expected to have a preventive effect such as suppressing the growth of fine metastatic cancer cells and further destroying it.
- a preventive effect such as suppressing the growth of fine metastatic cancer cells and further destroying it.
- Can the effect of suppressing and destroying cancer cells in body fluid in a metastasis process, and suppressing and destroying minute cancer cells immediately after implantation in any tissue can be expected. Therefore, suppression and prevention of cancer metastasis can be expected particularly after surgical removal of cancer.
- the pharmaceutical composition comprising the antibody-drug conjugate produced according to the present invention can also be administered in combination with other cancer therapeutic agents, which can enhance the antitumor effect.
- cancer therapeutic agents used for such purpose include 5-fluorouracil (5-FU), pertuzumab (Pertuzumab), trastuzumab (Trastuzumab), paclitaxel (Paclitaxel), carboplatin (Carboplatin), cisplatin (Cisplatin), Gemcitabine (Gemcitabine), Capecitabine (Capecitabine), Irinotecan (IPT), Docetaxel (Docetaxel), Pemetrexed (Pemetrexed), Sorafenib (Sorafenib), Vinblastine (Vinblastin), Vinorellibel Tanespimycin (Tan spimycin), bevacizumab (Bevacizumab), oxaliplatin (Oxaliplatin), lapatinib (Lapatinib),
- 1 H-NMR and 13 C-NMR in the examples mean “nuclear magnetic resonance spectrum”
- CDCl 3 in parenthesis means deuterated chloroform which is a measurement solvent
- DMSO-d 6 is The measurement solvent is heavy dimethyl sulfoxide
- D 2 O is the measurement solvent heavy water
- MeOH-d 4 is the measurement solvent heavy methanol.
- TMS tetramethylsilane was used as an internal standard substance.
- N-[(benzyloxy) carbonyl] glycylglycyl-L-phenylalanine 80 mg was added and the mixture was stirred at room temperature for about 6 hours. The precipitate was filtered off and the filtered off powder was washed with water (160 mL). The obtained powder was dried at 40 ° C. under reduced pressure to obtain N-[(benzyloxy) carbonyl] glycylglycyl-L-phenylalanine (157.2 g, 0.380 mol, yield 78.0%).
- Tetrahydrofuran (9.75 L) and acetic acid (1.95 L) were added to N-[(9H-fluoren-ylmethoxy) carbonyl] glycylglycine (650.0 g, 1.834 mol), and dissolved by heating to 40 ° C. .
- Lead tetraacetate (1301.3 g, 2.935 mol) was added and refluxed for about 1.5 hours. The mixture was cooled to room temperature, the insolubles were filtered off, and the filtered off insolubles were washed with ethyl acetate (3.25 L) and matched with the filtrate.
- Acetonitrile (10.2 L) mixture of benzyl [( ⁇ N-[(9H-fluoren-9-ylmethoxy) carbonyl] glycyl ⁇ amino] methoxy] acetate (340.0 g, 0.717 mol) in 1,8-diazabicyclo [ 5,4,0] -7-Undecene (53.6 mL, 0.358 mol) was added and stirred at room temperature for about 2 hours.
- Ethyl acetate (3.4 L) and water (1.7 L) were added, the layers were separated, and the aqueous layer was removed.
- a 10 (w / v)% aqueous potassium hydrogen carbonate solution (3.4 L) was added and stirred, and the mixture was separated to remove the aqueous layer.
- a 10 (w / v)% aqueous potassium hydrogen carbonate solution (3.4 L) was added and stirred, and the mixture was separated to remove the aqueous layer.
- Water (3.4 L) was added and the mixture was stirred, separated, the aqueous layer was removed, and concentrated to 1.5 L under reduced pressure. Add 2-methoxyethanol (3.74 L) and concentrate under reduced pressure to 3.06 L.
- the mixture was transferred to a 20 L autoclave, and tetrahydrofuran (1.36 L), water (3.4 L), 5% palladium carbon (72.6 g, moisture 53.2%) were added, and the atmosphere was replaced with hydrogen. After stirring for about 19 hours at room temperature, the atmosphere was replaced with nitrogen, water (360 mL) was added, and stirred for about 30 minutes at room temperature. The palladium on carbon was filtered off and palladium on carbon was washed with water (1.36 L) and matched with the filtrate. Ethyl acetate (0.85 L) and n-heptane (2.55 L) were added and stirred, then separated to remove the organic layer and concentrated under reduced pressure to 1.6 L.
- a solution of 6-aminohexanoic acid (2.5 kg, 19.1 mol) in acetic acid (10 L) is treated with a solution of maleic anhydride (1.87 kg, 19.1 mol) in acetic acid (10 L) at 25-30 ° C. for 1 hour
- the solution was added dropwise and stirred at the same temperature for 2 hours.
- Sulfuric acid (0.93 kg, 9.55 mol) was added dropwise to the obtained slurry, and the mixture was heated to 100 ° C. and stirred for 16 hours.
- the reaction solution was cooled to 30 ° C. and concentrated to 7.0 L under reduced pressure.
- the resulting concentrate (about 7.0 L) was added dropwise to cold water (20 L) at 0-5 ° C.
- the obtained 6- (2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl) hexanoic acid (1.40 kg, 6.66 mol) was dissolved in acetic acid (2.1 L), purified water (1. The mixture was dissolved in 4 L of the mixture at 25-30 ° C., purified water (0.7 L) was added, and the mixture was cooled to 20-25 ° C. and stirred for 2 hours. Purified water (7.0 L) was added dropwise to the resulting suspension over 1 hour, and after cooling to 0-5 ° C., the mixture was stirred for 1 hour. The precipitate was filtered off and the filtered off powder was washed with cold water (2.1 L). The obtained powder was dried at 40 ° C. under reduced pressure, and 6- (2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl) hexanoic acid (1.27 kg, 6.02 mol, yield 90) .4%).
- Acetonitrile of 6- (2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl) hexanoic acid (5.0 g, 23.6 mmol), N-hydroxysuccinimide (3.0 g, 26.0 mmol)
- 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (5.45 g, 28.4 mmol) and stirred at room temperature for about 3.5 hours.
- Water (100 mL) and toluene (100 mL) were added and stirred, and then separated to remove the aqueous layer.
- Acetonitrile of 6- (2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl) hexanoic acid (1.1 kg, 5.21 mol), N-hydroxysuccinimide (0.72 kg, 6.25 mol)
- the (11 L) mixture is cooled to -15 ° C, and 2,6-lutidine (1.34 kg, 12.50 mol) is added, and then thionyl chloride (0.74 kg, 6.25 mol) is added to -15 ° C to -10. It dripped over 1 hour at ° C. Water (11 L) and toluene (11 L) were added and stirred, and then separated to remove the aqueous layer.
- the organic layer is washed twice with cold water (11 L) at 0-5 ° C. and with 20% brine (11 L) at 0-5 ° C., and the organic layer is concentrated to 5.5 L under reduced pressure, and then toluene (5.5 L) Was again concentrated under reduced pressure to 5.5 L again.
- Acetonitrile (1 of 1- ⁇ 6-[(2,5-dioxopyrrolidin-1-yl) oxy] -6-oxohexyl ⁇ -1H-pyrrole-2,5-dione (291.3 g, 0.945 mol)
- Glycylglycyl-L-phenylalanyl-N-[(carboxymethoxy) methyl] glycinamide (200.0 g, 0.472 mol), water (4.2 L), N, N-diisopropylethylamine (48 L) solution. .8 g, 0.378 mol) was added and stirred at room temperature for about 9 hours.
- 1,2-dimethoxyethane (250.0 mL) was added dropwise, and the mixture was stirred at room temperature for about 5 hours, and concentrated under reduced pressure to 1.0 L. After adding 1,2-dimethoxyethane (1.0 L) dropwise and stirring at room temperature for about 1 hour, the solution was concentrated under reduced pressure to 1.0 L. After adding 1,2-dimethoxyethane (250.0 mL) dropwise and stirring at room temperature for about 16 hours, the precipitate was filtered and the filtered powder was washed with 1,2-dimethoxyethane (250.0 L). To the obtained wet powder was added 1,2-dimethoxyethane (2.0 L) and water (65.0 mL), and the temperature was raised to 45.degree.
- the resulting powder is dried at 25 ° C. under reduced pressure (4 kPa), N- [6- (2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl) hexanoyl] glycylglycyl-L-phenylara.
- the 1,2-dimethoxyethane adduct of nyl-N-[(carboxymethoxy) methyl] glycinamide (65.7 g, 0.107 mol, yield 90.3%) was obtained as crystals.
- Powder X-ray diffraction The crystals of the title compound were subjected to powder X-ray diffraction obtained by irradiation with copper K ⁇ radiation. The results are shown in Table 1 and FIG. Main peaks were observed at diffraction angles (2 ⁇ ) of 19.0 ° and 25.0 °.
- Powder X-ray diffraction The crystals of the title compound were subjected to powder X-ray diffraction obtained by irradiation with copper K ⁇ radiation. The results are shown in Table 2 and FIG. Major peaks were observed at diffraction angles (2 ⁇ ) of 5.6 °, 15.5 °, and 22.0 °.
- N, N-dimethylacetamide (15.0 kg) of benzyl [( ⁇ N-[(9H-fluoren-9-ylmethoxy) carbonyl] glycyl ⁇ amino] methoxy] acetate (2.28 kg, 4.81 mol) under nitrogen atmosphere
- 1,8-diazabicyclo [5.4.0] undec-7-ene (0.37 kg, 2.4 mol) and stirred at room temperature for 30 minutes.
- the obtained organic layer was separated and washed with a 10% aqueous citric acid solution (11.4 L). Tetrahydrofuran (20 kg) and a 15% aqueous potassium hydrogen carbonate solution (22.8 L) were added to the obtained organic layer, and the mixture was separated by stirring. The obtained organic layer was separated and washed with 10% brine (22.8 L). The obtained organic layer was concentrated under reduced pressure until the liquid volume reached about 6.8 L, and 2-propanol (12.4 kg) was added. The solution was concentrated again under reduced pressure until the liquid volume reached about 6.8 L, and 2-propanol (30.2 kg) was added to the obtained concentrate under heating at about 50 ° C. The mixture was stirred at the same temperature for 1 hour, cooled to about 5 ° C., and stirred for another 2 hours.
- the precipitated solid was filtered, and the filtered solid was washed with 2-propanol (14.2 kg) cooled to about 5 ° C.
- the obtained crystal 2 is suspended in 2-propanol (36 kg) and stirred at about 5 ° C. for 1 hour, and then the precipitated solid is filtered and the filtered solid is cooled to about 5 ° C.
- 2-propanol It was washed with (28.5 kg).
- the obtained crystals were dried at 50 ° C. under reduced pressure to obtain the title compound (3.34 kg, yield 94%).
- Tetrahydrofuran (5.88 kg) of benzyl [( ⁇ N-[(9H-fluoren-9-ylmethoxy) carbonyl] glycylglycyl-L-phenylalanyl ⁇ amino) methoxy] acetate (367 g, 0.499 mol), water (1. 8 kg).
- Palladium carbon-ethylenediamine complex 28 g was added to the suspension, and the mixture was stirred at room temperature under an atmosphere of hydrogen gas at normal pressure for 1 hour to 3 hours. The catalyst was filtered off, and the filtered catalyst was washed with tetrahydrofuran (1.63 kg) to obtain a filtrate.
- the reaction and the filtration of the catalyst were repeated nine times, and the obtained nine filtrates were combined.
- the solution was concentrated to about 17 L under reduced pressure.
- An operation of adding 2-propanol (39 kg) to the obtained concentrated solution and concentrating the solution to about 17 L under reduced pressure was repeated three times.
- Ethyl acetate (45 kg) was added to the obtained concentrate and stirred at room temperature for 6 hours.
- the suspension was further stirred at about 5 ° C. for 1 hour.
- the precipitated solid was filtered, and the filtered solid was washed with a 1: 3 mixture (23.1 L) of 2-propanol and ethyl acetate cooled to about 5 ° C.
- the crystals obtained were dried at 40 ° C.
- Tetrahydrofuran (3.9 L), ethyl acetate (2.6 L) and 11% aqueous potassium hydrogen carbonate solution (5.2 L) were added, and the mixture was stirred and separated.
- the obtained organic layer was washed successively with 19% aqueous citric acid solution (3.9 L), 22% aqueous potassium hydrogen carbonate solution (2.6 L), and 18% brine (0.78 L).
- Activated carbon (52 g) was added to the obtained organic layer, and after stirring for 30 minutes, tetrahydrofuran (0.78 L) and anhydrous magnesium sulfate (0.78 g) were added and stirred for 30 minutes. The solid was filtered off and the filtered solid was washed with tetrahydrofuran (0.78 L).
- the obtained filtrate was concentrated to about 200 mL under reduced pressure.
- Ethyl acetate (1.3 L) was added to the obtained concentrate, and the solution was concentrated to about 200 mL under reduced pressure.
- Tetrahydrofuran (1.8 L) was added to the obtained concentrate.
- the resulting solution was added dropwise to a mixture of ethyl acetate (1.3 L) and cyclopentyl methyl ether (1.3 L) prepared in a separate container over 12 minutes. To this suspension was added cyclopentyl methyl ether (2.6 L) and stirred for 18 hours, then cooled to about 5 ° C. and stirred for an additional hour.
- the precipitated solid was filtered off, and the filtered off solid was washed with a 1: 3 mixture of tetrahydrofuran and cyclopentyl methyl ether (1.3 L). The obtained solid was dried at 40 ° C. under reduced pressure to obtain the title compound (408 g, yield 84%).
- the precipitated solid was filtered under a stream of nitrogen, and the filtered off solid was washed with tetrahydrofuran (2.4 L). The obtained solid was dried at 40 ° C. under reduced pressure to obtain a mixture (363 g, yield 115%) containing the title compound.
- Acetone (0.4 mL) and 2-butanol (0.2 mL) are added to 19.5 mg of the obtained oil, and the mixture is warmed to about 60 ° C.
- the precipitated solid is filtered at room temperature and the filtered solid is collected.
- the residue was washed with 2-butanol (about 0.2 mL) to give the title compound (14.3 mg) as a colorless powder.
- the obtained powder was used as a seed crystal for the next reaction.
- the obtained organic layer is added dropwise to a suspension of activated carbon (35 g) in acetonitrile (35 L) prepared in a separate container and stirred for 30 minutes, and then the activated carbon is filtered off and the separated activated carbon is acetonitrile (1.8 L) Washed with The obtained filtrate was concentrated under reduced pressure at an external temperature of about 40 ° C. until no solvent was distilled off. Acetone (1.8 L) and 1-propanol (3.5 L) were sequentially added to the obtained concentrated residue, and the mixture was heated to 55 ° C. for dissolution, and then cooled to room temperature.
- Example 21 The powder (0.2 g) obtained in Example 21 was added as seed crystals, and after stirring for 86 hours, the precipitated solid was filtered, and the filtered off solid was washed with acetone (1.1 L). The obtained solid was dried at 40 ° C. under reduced pressure to give the title compound (191 g, yield 44%) as crystals.
- Activated carbon (0.30 g, strong white glaze (Osaka Gas Chemical Co., Ltd.)) was added and stirred at room temperature for about 15 minutes or more, then the activated carbon was filtered off and the activated carbon was washed with tetrahydrofuran (9 mL) to match the filtrate The solution was concentrated under reduced pressure to 30 mL. Tetrahydrofuran (75 mL) was added to the concentrate, concentrated under reduced pressure to 30 mL, tetrahydrofuran (45 mL) was further added, and concentrated under reduced pressure to 30 mL.
- SEQ ID NO: 1 amino acid sequence of anti-HER2 antibody heavy chain
- SEQ ID NO: 2 amino acid sequence of anti-HER2 antibody light chain
- SEQ ID NO: 3 amino acid sequence of heavy chain of anti HER3 antibody
- SEQ ID NO: 4 amino acid sequence of light chain of anti HER3 antibody
- SEQ ID NO: 5 amino acid sequence of anti-TROP2 antibody heavy chain
- SEQ ID NO: 6 amino acid sequence of anti-TROP2 antibody light chain
- SEQ ID NO: 7 amino acid sequence of anti-B7-H3 antibody heavy chain
- SEQ ID NO: 8 anti-B7-H3 antibody light chain
- SEQ ID NO: 10 amino acid sequence of anti-GPR20 antibody light chain
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
[1]
式(1)
[2]
銅のKα線の照射で得られる粉末X線回折において、5.6±0.2°、15.5±0.2°、及び22.0±0.2°の回折角度(2θ)に主要なピークを示す、[1]に記載の結晶。
[3]
式(1)
[4]
式(1)で表される化合物の結晶が、銅のKα線の照射で得られる粉末X線回折において、5.6±0.2°、15.5±0.2°、及び22.0±0.2°の回折角度(2θ)に主要なピークを示す、[3]に記載の製造方法。
[5]
式(1)で表される化合物が溶解した溶液が、低級ケトンと低級アルコールを溶媒として含む、[3]又は[4]に記載の製造方法。
[6]
低級ケトンがアセトンである、[5]に記載の製造方法。
[7]
低級ケトンがメチルエチルケトンである、[5]に記載の製造方法。
[8]
低級アルコールが1-プロパノールである、[5]から[7]のいずれか1項に記載の製造方法。
[9]
低級アルコールが2-ブタノールである、[5]から[7]のいずれか1項に記載の製造方法。
[10]
式(1)で表される化合物の結晶の種晶を添加する工程を含む、[3]から[9]のいずれか1項に記載の製造方法。
[11]
式(1)で表される化合物が、製造方法(I)によって製造されることを特徴とする、[3]から[10]のいずれか1項に記載の製造方法;
(ここで、製造方法(I)は、
式(B)
式(8)
式(C)
式(10)
式(1)
[12]
式(1)で表される化合物が、製造方法(II)によって製造されることを特徴とする、[3]から[10]のいずれか1項に記載の製造方法;
(ここで、製造方法(II)は、
式(B)
式(D)
式(C)
式(E)
式(10)
式(1)
[13]
1,2-ジメトキシエタンを含む溶媒に、式(10)で表される化合物を溶解させる工程、次いで、式(10)で表される化合物の1,2-ジメトキシエタン付加物の結晶を析出させる工程、を含む、[11]又は[12]のいずれか1項に記載の製造方法。
[14]
式(10)で表される化合物の1,2-ジメトキシエタン付加物の結晶が、銅のKα線の照射で得られる粉末X線回折において、19.0±0.2°、及び25.0±0.2°の回折角度(2θ)に主要なピークを示す、[13]に記載の製造方法。
[15]
式(10)で表される化合物と、式(11)で表される化合物を縮合することにより、
式(1)で表される化合物へ変換する工程が、硫酸ナトリウム水溶液とテトラヒドロフランの2相系中にて行われる、[11]から[14]のいずれか1項に記載の製造方法。
[16]
式(1)で表される化合物が、製造方法(III)によって製造されることを特徴とする、[3]から[10]のいずれか1項に記載の製造方法;
(ここで、製造方法(III)は、
式(B)
式(F)
式(11)
式(G)
式(16)
式(C)
式(1)
[17]
式(11)で表される化合物が、メタンスルホン酸塩である、[11]から[16]のいずれか1項に記載の製造方法。
[18]
式(11)で表される化合物が、メタンスルホン酸塩・m水和物(ここで、mは0~3個の範囲内である)である、[11]から[16]のいずれか1項に記載の製造方法。
[19]
式(11)で表される化合物が、メタンスルホン酸塩・無水物である、[11]から[16]のいずれか1項に記載の製造方法。
[20]
式(11)で表される化合物が、メタンスルホン酸塩・1水和物である、[11]から[16]のいずれか1項に記載の製造方法。
[21]
式(11)で表される化合物が、メタンスルホン酸塩・2水和物である、[11]から[16]のいずれか1項に記載の製造方法。
[22]
式(11)で表される化合物が、メタンスルホン酸塩・3水和物である、[11]から[16]のいずれか1項に記載の製造方法。
[23]
式(B)で表される化合物が、製造方法(IV)によって製造されることを特徴とする、[11]から[22]のいずれか1項に記載の製造方法;
(ここで、製造方法(IV)は、
式(H)
式(J)
式(K)
式(L)
式(M)
式(N)
式(B)
[24]
式(H)で表される化合物を四酢酸鉛と反応させることにより式(J)で表される化合物へ変換する工程が、酢酸の存在下で行われる、[23]に記載の製造方法。
[25]
式(J)で表される化合物と式(K)で表される化合物を反応させ、式(L)で表される化合物へ変換する工程が、水酸化ナトリウム水溶液の存在下で行われる、[23]又は[24]に記載の製造方法。
[26]
式(J)で表される化合物と式(K)で表される化合物を反応させ、式(L)で表される化合物へ変換する工程が、トリス(ペンタフルオロフェニル)ボランの存在下で行われる、[23]又は[24]に記載の製造方法。
[27]
式(L)で表される化合物のアミノ基の保護基を脱保護することにより、式(M)で表される化合物へ変換する工程の後、酸を添加することにより、式(M)で表される化合物と酸との塩を析出させる工程を含む、[23]から[26]のいずれか1項に記載の製造方法。
[28]
酸が、1-ヒドロキシベンゾトリアゾールである、[27]に記載の製造方法。
[29]
R1がベンジルオキシカルボニル基で保護されたアミノ基である、[11]から[28]のいずれか1項に記載の製造方法。
[30]
R1が(9H-フルオレン-9-イルメトキシ)カルボニル基で保護されたアミノ基である、[11]から[28]のいずれか1項に記載の製造方法。
[31]
R2がベンジル基で保護されたカルボキシ基である、[11]から[30]のいずれか1項に記載の製造方法。
[32]
R3が(9H-フルオレン-9-イルメトキシ)カルボニル基で保護されたアミノ基である、[23]から[31]のいずれか1項に記載の製造方法。
[33]
Xが(2,5-ジオキソピロリジン-1-イル)オキシカルボニル基である、[11]から[32]のいずれか1項に記載の製造方法。
[34]
式(1)で表される化合物が、製造方法(V)によって製造されることを特徴とする、[3]から[10]のいずれか1項に記載の製造方法;
(ここで、製造方法(V)は、
式(2)
式(3)
式(4)
式(5)
式(6)
式(7)
式(8)
式(9)
式(10)
式(1)
[35]
1,2-ジメトキシエタンを含む溶媒に、式(10)で表される化合物を溶解させる工程、次いで、式(10)で表される化合物の1,2-ジメトキシエタン付加物の結晶を析出させる工程、を含む、[34]に記載の製造方法。
[36]
式(10)で表される化合物の1,2-ジメトキシエタン付加物の結晶が、銅のKα線の照射で得られる粉末X線回折において、19.0±0.2°、及び25.0±0.2°の回折角度(2θ)に主要なピークを示す、[35]に記載の製造方法。
[37]
式(10)で表される化合物と、式(11)で表される化合物を縮合することにより、式(1)で表される化合物へ変換する工程が、硫酸ナトリウム水溶液とテトラヒドロフランの2相系中にて行われる、[34]から[36]のいずれか1項に記載の製造方法。
[38]
式(1)で表される化合物が、製造方法(VI)によって製造されることを特徴とする、[3]から[10]のいずれか1項に記載の製造方法;
(ここで、製造方法(VI)は、
式(2)
式(3)
式(4)
式(5)
式(12)
式(13)
式(14)
式(11)
式(15)
式(16)
式(9)
式(1)
[39]
式(2)で表される化合物を四酢酸鉛と反応させることにより式(3)で表される化合物へ変換する工程が、酢酸の存在下で行われる、[34]から[38]のいずれか1項に記載の製造方法。
[40]
式(3)で表される化合物を式(4)で表される化合物へ変換する工程が、水酸化ナトリウム水溶液の存在下で行われる、[34]から[39]のいずれか1項に記載の製造方法。
[41]
式(3)で表される化合物を式(4)で表される化合物へ変換する工程が、トリス(ペンタフルオロフェニル)ボランの存在下で行われる、[34]から[39]のいずれか1項に記載の製造方法。
[42]
式(4)で表される化合物のアミノ基の保護基を脱保護することにより、式(5)で表される化合物へ変換する工程の後、酸を添加することにより、式(5)で表される化合物と酸との塩を析出させる工程を含む、[34]から[41]のいずれか1項に記載の製造方法。
[43]
酸が、1-ヒドロキシベンゾトリアゾールである、[42]に記載の製造方法。
[44]
式(6)で表される化合物が、
式(23)
式(24)
[45]
式(9)で表される化合物が、
式(17)
式(18)
[46]
式(11)で表される化合物が、メタンスルホン酸塩である、[34]から[45]のいずれか1項に記載の製造方法。
[47]
式(11)で表される化合物が、メタンスルホン酸塩・m水和物(ここで、mは0~3個の範囲内である)である、[34]から[45]のいずれか1項に記載の製造方法。
[48]
式(11)で表される化合物が、メタンスルホン酸塩・無水物である、[34]から[45]のいずれか1項に記載の製造方法。
[49]
式(11)で表される化合物が、メタンスルホン酸塩・1水和物である、[34]から[45]のいずれか1項に記載の製造方法。
[50]
式(11)で表される化合物が、メタンスルホン酸塩・2水和物である、[34]から[45]のいずれか1項に記載の製造方法。
[51]
式(11)で表される化合物が、メタンスルホン酸塩・3水和物である、[34]から[45]のいずれか1項に記載の製造方法。
[52]
式(H)
式(J)
[53]
R3が(9H-フルオレン-9-イルメトキシ)カルボニル基で保護されたアミノ基である、[52]に記載の製造方法。
[54]
式(J)
式(K)
式(L)
[55]
水酸化ナトリウム水溶液の存在下で反応させることを特徴とする、[54]に記載の製造方法。
[56]
トリス(ペンタフルオロフェニル)ボランの存在下で反応させることを特徴とする、[54]に記載の製造方法。
[57]
R2がベンジル基で保護されたカルボキシ基である、[54]から[56]のいずれか1項に記載の製造方法。
[58]
R3が(9H-フルオレン-9-イルメトキシ)カルボニル基で保護されたアミノ基である、[54]から[57]のいずれか1項に記載の製造方法。
[59]
式(L)
式(M)
[60]
酸が、1-ヒドロキシベンゾトリアゾールである、[59]に記載の製造方法。
[61]
R2がベンジル基で保護されたカルボキシ基である、[59]又は[60]に記載の製造方法。
[62]
R3が(9H-フルオレン-9-イルメトキシ)カルボニル基で保護されたアミノ基である、[59]から[61]のいずれか1項に記載の製造方法。
[63]
式(18)
式(9)
[64]
式(18)で表される化合物が、
式(17)
[65]
1,2-ジメトキシエタンを含む溶媒に、
式(10)
[66]
式(10)で表される化合物の1,2-ジメトキシエタン付加物の結晶が、銅のKα線の照射で得られる粉末X線回折において、19.0±0.2°、及び25.0±0.2°の回折角度(2θ)にピークを示す、[65]に記載の製造方法。
[67]
式(10)
式(11)
式(1)
[68]
式(11)で表される化合物が、メタンスルホン酸塩である、[67]に記載の製造方法。
[69]
式(11)で表される化合物が、メタンスルホン酸塩・m水和物(ここで、mは0~3個の範囲内である)である、[67]に記載の製造方法。
[70]
式(11)で表される化合物が、メタンスルホン酸塩・無水物である、[67]に記載の製造方法。
[71]
式(11)で表される化合物が、メタンスルホン酸塩・1水和物である、[67]に記載の製造方法。
[72]
式(11)で表される化合物が、メタンスルホン酸塩・2水和物である、[67]に記載の製造方法。
[73]
式(11)で表される化合物が、メタンスルホン酸塩・3水和物である、[67]に記載の製造方法。
[74]
クロマトグラフィーを使用しないことを特徴とする、[3]から[73]のいずれか1項に記載の製造方法。
[75]
式(10)
[76]
銅のKα線の照射で得られる粉末X線回折において、19.0±0.2°、及び25.0±0.2°の回折角度(2θ)に主要なピークを示す、[75]に記載の結晶。
[77]
式(5)
[78]
酸が1-ヒドロキシベンゾトリアゾールである、[77]に記載の塩。
[79]
[3]から[51]のいずれか1項に記載された方法により製造された
式(1)
i)抗体を、還元する工程、次いで、
ii)上記方法で製造された式(1)で表される化合物の結晶が溶解した溶液を添加し、還元された抗体と反応させる工程、
を含む、
式(19)
で示される薬物リンカーと、抗体とがチオエーテル結合によって結合した抗体-薬物コンジュゲートの製造方法。
[80]
抗体が、抗HER2抗体、抗HER3抗体、抗TROP2抗体、抗B7-H3抗体、又は抗GPR20抗体である、[79]に記載の製造方法。
[81]
抗体が、抗HER2抗体である、[80]に記載の製造方法。
[82]
抗HER2抗体が、配列番号1においてアミノ酸番号1乃至449に記載のアミノ酸配列からなる重鎖及び配列番号2においてアミノ酸番号1乃至214に記載のアミノ酸配列からなる軽鎖を含んでなる抗体、又は、配列番号1に記載のアミノ酸配列からなる重鎖及び配列番号2に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、[81]に記載の製造方法。
[83]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7から8個の範囲である、[81]又は[82]に記載の製造方法。
[84]
抗体が、抗HER3抗体である、[80]に記載の製造方法。
[85]
抗HER3抗体が、配列番号3に記載のアミノ酸配列からなる重鎖及び配列番号4に記載のアミノ酸配列からなる軽鎖を含んでなる抗体、又は、該抗体の重鎖カルボキシル末端のリシン残基が欠失している抗体である、[84]に記載の製造方法。
[86]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7から8個の範囲である、[84]又は[85]に記載の製造方法。
[87]
抗体が、抗TROP2抗体である、[80]に記載の製造方法。
[88]
抗TROP2抗体が、配列番号5においてアミノ酸番号20乃至470に記載のアミノ酸配列からなる重鎖及び配列番号6においてアミノ酸番号21乃至234に記載のアミノ酸配列からなる軽鎖を含んでなる抗体、又は、該抗体の重鎖カルボキシル末端のリシン残基が欠失している抗体である、[87]に記載の製造方法。
[89]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が3から5個の範囲である、[87]又は[88]に記載の製造方法。
[90]
抗体が、抗B7-H3抗体である、[80]に記載の製造方法。
[91]
抗B7-H3抗体が、配列番号7においてアミノ酸番号20乃至471に記載のアミノ酸配列からなる重鎖及び配列番号8においてアミノ酸番号21乃至233に記載のアミノ酸配列からなる軽鎖を含んでなる抗体、又は、該抗体の重鎖カルボキシル末端のリシン残基が欠失している抗体である、[90]に記載の製造方法。
[92]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が3から5個の範囲である、[90]又は[91]に記載の製造方法。
[93]
抗体が、抗GPR20抗体である、[80]に記載の製造方法。
[94]
抗GPR20抗体が、配列番号9においてアミノ酸番号20乃至472に記載のアミノ酸配列からなる重鎖及び配列番号10においてアミノ酸番号21乃至234に記載のアミノ酸配列からなる軽鎖を含んでなる抗体、又は、該抗体の重鎖カルボキシル末端のリシン残基が欠失している抗体である、[93]に記載の製造方法。
[95]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7から8個の範囲である、[93]又は[94]に記載の製造方法。
に関する。
本発明によって製造される抗体-薬物コンジュゲートは、
式(19)
で示される薬物リンカーと、抗体とがチオエーテル結合によって結合した抗体-薬物コンジュゲートである。
式(11)
式(20)
式(22)
式(22)で表される化合物は、本発明によって製造される抗体-薬物コンジュゲートの抗腫瘍活性の本体であると考えられ、トポイソメラーゼI阻害作用を有することが確認されている(Ogitani Y. et al., Clinical Cancer Research, 2016, Oct 15;22(20):5097-5108, Epub 2016 Mar 29)。
式(21)
本発明の抗体-薬物コンジュゲートの製造に使用される薬物リンカー中間体は、
式(1)
製造方法(I)は、式(B)で表される化合物から、工程1~3を経て式(1)で表される化合物へ変換する方法である。以下、工程1~3について詳細に説明する。
本工程は、式(B)で表される化合物のアミノ基及びカルボキシ基の保護基を脱保護することにより、式(8)で表される化合物へ変換する工程である。
本工程は、式(8)で表される化合物と、式(C)で表される化合物を縮合することにより、式(10)で表される化合物へ変換する工程である。式(C)で表される化合物は市販のもの、又は公知の方法により製造したもの、又は、下記の製造方法(VII)に準じた方法により製造したものを用いることができる。Xが(2,5-ジオキソピロリジン-1-イル)オキシカルボニル基である場合、本工程は、好適には、以下の方法で行うことができる。
本工程は、式(10)で表される化合物と、式(11)で表される化合物を縮合することにより、式(1)で表される化合物へ変換する工程である。式(11)で表される化合物は、好適には、メタンスルホン酸塩として用いることができ、より好適には、メタンスルホン酸塩・m水和物(ここでmは0~3個である)として用いることができ、更により好適には、メタンスルホン酸塩・無水物、メタンスルホン酸塩・1水和物、メタンスルホン酸塩・2水和物、又はメタンスルホン酸塩・3水和物として用いることができ、更により好適には、メタンスルホン酸塩・2水和物として用いることができるが、いずれも本発明の製造方法に用いることができる。なお、上記の水和物数は、結晶取得・乾燥時の湿度を調整することにより、コントロールすることができる。
製造方法(II)は、式(B)で表される化合物から、工程4~7を経て式(1)で表される化合物へ変換する方法である。以下、工程4~7について詳細に説明する。
本工程は、式(B)で表される化合物のアミノ基の保護基を脱保護することにより、式(D)で表される化合物へ変換する工程である。
本工程は、式(D)で表される化合物と、式(C)で表される化合物を縮合することにより、式(E)で表される化合物へ変換する工程である。
本工程は、式(E)で表される化合物のカルボキシ基の保護基を脱保護することにより、式(10)で表される化合物へ変換する工程である。
本工程は、式(10)で表される化合物と、式(11)で表される化合物を縮合することにより、式(1)で表される化合物へ変換する工程である。
製造方法(III)は、式(B)で表される化合物から、工程8~11を経て式(1)で表される化合物へ変換する方法である。以下、工程8~11について詳細に説明する。
本工程は、式(B)で表される化合物のカルボキシ基の保護基を脱保護することにより、式(F)で表される化合物へ変換する工程である。
本工程は、式(F)で表される化合物と、式(11)で表される化合物を縮合することにより、式(G)で表される化合物へ変換する工程である。
本工程は、式(G)で表される化合物のアミノ基の保護基を脱保護することにより、式(16)で表される化合物へ変換する工程である。
本工程は、式(16)で表される化合物と、式(C)で表される化合物を縮合することにより、式(1)で表される化合物へ変換する工程である。式(C)で表される化合物は市販のもの、公知の方法により製造したもの、又は、下記の製造方法(VII)に準じた方法により製造したものを用いることができる。Xが(2,5-ジオキソピロリジン-1-イル)オキシカルボニル基である場合、本工程は、好適には、以下の方法で行うことができる。
製造方法(IV)は、式(H)で表される化合物から、工程12~15を経て式(B)で表される化合物へ変換する方法である。以下、工程12~15について詳細に説明する。
工程12:
本工程は、式(H)で表される化合物を、四酢酸鉛と反応させることにより、式(J)で表される化合物へ変換する工程である。式(H)で表される化合物は、市販のもの又は公知の方法を参考に製造したものを用いることができる。本工程に用いられる四酢酸鉛の量は、反応が進行する限り制限されないが、好適には、式(H)で表される化合物に対して、1~3当量である。
本工程は、式(J)で表される化合物と式(K)で表される化合物を、酸又は塩基の存在下で反応させることにより、式(L)で表される化合物へ変換する工程である。本工程に用いられる式(K)で表される化合物の量は、反応が進行する限り制限されないが、好適には、式(J)で表される化合物に対して、1~4当量である。
本工程は、式(L)で表される化合物のアミノ基の保護基を脱保護することにより、式(M)で表される化合物へ変換する工程である。
式(L)で表される化合物のアミノ基の保護基の脱保護は、反応が進行する限り特に制限は無いが、例えば、1,8-ジアザビシクロ[5,4,0]-7-ウンデセン、トリメチルグアニジン、1,5,7-トリアザビシクロ[4,4,0]デカ-5-エン、又は7-メチル-1,5,7-トリアザビシクロ[4,4,0]デカ-5-エン1,5-ジアザビシクロ[4,3,0]-5-ノネンを用いて行うことができ、好適には、1,8-ジアザビシクロ[5,4,0]-7-ウンデセンを用いて行うことができる。本工程に用いられる1,8-ジアザビシクロ[5,4,0]-7-ウンデセンの量は、反応が進行する限り制限されないが、好適には、式(L)で表される化合物に対して、0.25~1当量である。
上記の酸は、好適には、1-ヒドロキシベンゾトリアゾールである。本工程で用いた1-ヒドロキシベンゾトリアゾールは、次の工程15において、縮合剤の一つとして機能することもできる。同様に、1-ヒドロキシベンゾトリアゾール以外の酸も、縮合剤の一つとして機能するものであれば、本工程に好適に用いることができる。
本工程は、式(M)で表される化合物と、式(N)で表される化合物を縮合することにより、式(B)で表される化合物へ変換する工程である。式(N)で表される化合物は市販のもの、公知の方法により製造したもの、又は、下記の製造方法(VIII)に準じた方法により製造したものを用いることができる。本工程に用いられる式(N)で表される化合物の量は、反応が進行する限り制限されないが、好適には、式(M)で表される化合物に対して、0.7~1.3当量である。
本工程の反応温度は、反応が進行する限り制限されないが、好適には、-10~15℃である。本工程の反応時間は、反応が進行する限り制限されないが、好適には、1.5~7時間である。
製造方法(V)は、式(2)で表される化合物から、工程16~22を経て式(1)で表される化合物へ変換する方法である。以下、工程16~22について詳細に説明する。
本工程は、式(2)で表される化合物を、四酢酸鉛と反応させることにより、式(3)で表される化合物へ変換する工程である。式(2)で表される化合物は、市販のもの又は公知の方法を参考に製造したものを用いることができる。本工程は、製造方法(IV)の工程12と同様の方法により、行うことができる。
本工程は、式(3)で表される化合物を、酸又は塩基の存在下で、グリコール酸ベンジルと反応させることにより、式(4)で表される化合物へ変換する工程である。本工程は、製造方法(IV)の工程13と同様の方法により、行うことができる。
本工程は、式(4)で表される化合物のアミノ基の保護基を脱保護することにより、式(5)で表される化合物へ変換する工程である。本工程は、製造方法(IV)の工程14と同様の方法により、行うことができる。
本工程は、式(5)で表される化合物と、式(6)で表される化合物を縮合することにより、式(7)で表される化合物へ変換する工程である。式(6)で表される化合物は、市販のもの、公知の方法により製造したもの、又は下記の製造方法(VIII)により製造したものを用いることができる。本工程は、製造方法(IV)の工程15と同様の方法により、行うことができる。
本工程は、式(7)で表される化合物のアミノ基及びカルボキシ基の保護基を脱保護することにより、式(8)で表される化合物へ変換する工程である。本工程は、製造方法(I)の工程1と同様の方法により、行うことができる。
本工程は、式(8)で表される化合物と、式(9)で表される化合物を縮合することにより、式(10)で表される化合物へ変換する工程である。本工程は、製造方法(I)の工程2と同様の方法により、行うことができる。
本工程は、式(10)で表される化合物と、式(11)で表される化合物を縮合することにより、式(1)で表される化合物へ変換する工程である。本工程は、製造方法(I)の工程3と同様の方法により、行うことができる。
製造方法(VI)は、式(2)で表される化合物から、工程23~30を経て式(1)で表される化合物へ変換する方法である。以下、工程23~30について詳細に説明する。
本工程は、式(2)で表される化合物を、四酢酸鉛と反応させることにより、式(3)で表される化合物へ変換する工程である。式(2)で表される化合物は、市販のもの又は公知の方法を参考に製造したものを用いることができる。本工程は、製造方法(IV)の工程12と同様の方法により、行うことができる。
本工程は、式(3)で表される化合物を、酸又は塩基の存在下で、グリコール酸ベンジルと反応させることにより、式(4)で表される化合物へ変換する工程である。本工程は、製造方法(IV)の工程13と同様の方法により、行うことができる。
本工程は、式(4)で表される化合物のアミノ基の保護基を脱保護することにより、式(5)で表される化合物へ変換する工程である。本工程は、製造方法(IV)の工程14と同様の方法により、行うことができる。
本工程は、式(5)で表される化合物と、式(12)で表される化合物を縮合することにより、式(13)で表される化合物へ変換する工程である。式(13)で表される化合物は市販のもの、又は公知の方法により製造したものを用いることができる。本工程は、製造方法(IV)の工程15と同様の方法により、行うことができる。
本工程は、式(13)で表される化合物のカルボキシ基の保護基を脱保護することにより、式(14)で表される化合物へ変換する工程である。本工程は、製造方法(III)の工程8と同様の方法により、行うことができる。
本工程は、式(14)で表される化合物と、式(11)で表される化合物を縮合することにより、式(15)で表される化合物へ変換する工程である。本工程は、製造方法(III)の工程9と同様の方法により、行うことができる。
本工程は、式(15)で表される化合物のアミノ基の保護基を脱保護することにより、式(16)で表される化合物へ変換する工程である。本工程は、製造方法(III)の工程10と同様の方法により、行うことができる。
本工程は、式(16)で表される化合物と、式(9)で表される化合物を縮合することにより、式(1)で表される化合物へ変換する工程である。本工程は、製造方法(III)の工程11と同様の方法により、行うことができる。
式(9)で表される化合物は、好適には、以下の製造方法(VII)により製造したものを用いることができる。これにより、以降の工程で製造される化合物の品質に影響を及ぼす可能性がある不純物を抑制することができ、高品質の式(1)で表される化合物の取得に寄与することができる。
本工程は、式(17)で表される化合物と無水マレイン酸を縮合することにより、式(18)で表される化合物へ変換する工程である。本工程に用いられる無水マレイン酸の量は、反応が進行する限り制限されないが、好適には、式(17)で表される化合物に対して、0.7~1.3当量である。
本工程は、式(18)で表される化合物とN-ヒドロキシスクシンイミドを縮合することにより、式(9)で表される化合物へ変換する工程である。本工程に用いられるN-ヒドロキシスクシンイミドの量は、反応が進行する限り制限されないが、好適には、式(17)で表される化合物に対して、0.7~1.3当量である。
式(6)で表される化合物は、以下の製造方法(VIII)により製造したものを用いることができる。
本工程は、式(23)で表される化合物をN-ヒドロキシスクシンイミドと縮合することにより、式(24)で表される化合物へ変換する工程である。本工程に用いられる式(23)で表される化合物の量は、反応が進行する限り制限されないが、好適には、式(23)で表される化合物に対して、0.7~1.5当量である。
本工程は、式(24)で表される化合物を、L-フェニルアラニンと縮合することにより、式(6)で表される化合物へ変換する工程である。本工程に用いられるL-フェニルアラニンの量は、反応が進行する限り制限されないが、好適には、式(24)で表される化合物に対して、0.7~1.3当量である。
式(1)で表される化合物は、以下の製造方法(IX)により製造されたものを用いることもできる。
本工程は、式(H)で表される化合物を、四酢酸鉛と反応させることにより、式(J)で表される化合物へ変換する工程である。式(H)で表される化合物は、市販のもの又は公知の方法を参考に製造したものを用いることができる。本工程は、製造方法(IV)の工程12と同様の方法により、行うことができる。
本工程は、式(J)で表される化合物を、酸又は塩基の存在下で、式(K)で表される化合物と反応させることにより、式(L)で表される化合物へ変換する工程である。本工程は、製造方法(IV)の工程13と同様の方法により、行うことができる。
本工程は、式(L)で表される化合物のカルボキシ基の保護基を脱保護することにより、式(O)で表される化合物へ変換する工程である。
本工程は、式(O)で表される化合物と、式(11)で表される化合物を縮合することにより、式(P)で表される化合物へ変換する工程である。
本工程は、式(P)で表される化合物のアミノ基の保護基を脱保護することにより、式(25)で表される化合物へ変換する工程である。
本工程は、式(25)で表される化合物と、式(N)で表される化合物を縮合することにより、式(G)で表される化合物へ変換する工程である。
本工程は、式(G)で表される化合物のアミノ基の保護基を脱保護することにより、式(16)で表される化合物へ変換する工程である。本工程は、製造方法(III)の工程10と同様の方法により、行うことができる。
本工程は、式(16)で表される化合物と、式(C)で表される化合物を縮合することにより、式(1)で表される化合物へ変換する工程である。本工程は、製造方法(III)の工程11と同様の方法により、行うことができる。
本発明の抗体-薬物コンジュゲートの製造に使用される抗体は、いずれの種に由来してもよいが、好適には、ヒト、ラット、マウス、及びウサギに由来する抗体である。抗体がヒト以外の種に由来する場合は、周知の技術を用いて、キメラ化又はヒト化することが好ましい。本発明の抗体は、ポリクローナル抗体であっても、モノクローナル抗体であってもよいが、モノクローナル抗体が好ましい。
抗GPR20抗体としては、例えば、h046-H4e/L7(国際公開第2018/135501号)を挙げることができる。
本発明の抗体-薬物コンジュゲートは、式(1)で表される化合物と、チオール基(又はスルフヒドリル基とも言う)を有する抗体を反応させることによって製造することができる。
本発明によって製造される抗体-薬物コンジュゲートは、1種以上の薬学的に適合性の成分を含み投与され得る。薬学的に適合性の成分は、本発明によって製造される抗体-薬物コンジュゲートの投与量や投与濃度等に応じて、この分野において通常使用される製剤添加物その他から適宜選択して適用することができる。例えば、本発明によって製造される抗体-薬物コンジュゲートは、ヒスチジン緩衝剤等の緩衝剤、スクロース又はトレハロース等の賦形剤、並びにポリソルベート80又はポリソルベート20等の界面活性剤を含む医薬組成物として投与され得る。
2,5-ジオキソピロリジン-1-イル N-[(ベンジルオキシ)カルボニル]グリシルグリシナート
13C-NMR (100MHz,DMSO-d6)δ25.4,38.2,43.3,65.6,127.7,127.8,128.3,137.0,156.5,166.3,170.0,170.0.
MS(ESI)(m/z):364([M+H]+).
N-[(ベンジルオキシ)カルボニル]グリシルグリシル-L-フェニルアラニン
13C-NMR (100MHz,DMSO-d6)δ36.8,41.6,43.5,53.5,65.5,126.5,127.7,127.8,128.2,128.3,129.1,137.0,137.4,156.5,168.6,169.3,172.7.
MS(ESI)(m/z):412([M-H]-).
({N-[(9H-フルオレン-9-イルメトキシ)カルボニル]グリシル}アミノ)メチルアセテート
13C-NMR (100MHz,CDCl3)δ20.8,44.4,47.0,63.9,67.2,120.0,125.0,127.1,127.7,141.3,143.6,156.6,169.8,171.7.
MS(ESI)(m/z):369([M+H]+).
ベンジル[({N-[(9H-フルオレン-9-イルメトキシ)カルボニル]グリシル}アミノ)メトキシ]アセテート
13C-NMR (100MHz,CDCl3)δ44.5,47.1,66.6,66.8,67.1,70.6,120.0,124.9,127.1,127.8,128.4,128.5,128.6,135.2,141.3,143.6,170.2,170.2,170.4.
MS(ESI)(m/z):475([M+H]+).
グリシルグリシル-L-フェニルアラニル-N-[(カルボキシメトキシ)メチル]グリシンアミド
13C-NMR (100MHz,D2O)δ37.3,41.0,42.7,43.2,56.0,67.3,70.0,127.8,129.4,129.8,136.9,168.4,171.7,172.9,174.4,178.1.
MS(ESI)(m/z):422([M-H]-).
ベンジル[(グリシルアミノ)メトキシ]アセテート 1H-ベンゾトリアゾール-1-オール
13C-NMR (125MHz,MeOH-d4)δ41.9,66.3,67.6,71.0,112.3,118.7,125.24,125.27,128.8,129.25,129.30,129.5,136.9,144.4,169.5,171.8
N-[(ベンジルオキシ)カルボキシル]グリシルグリシル-L-フェニルアラニル-N-{[2-(ベンジルオキシ)-2-オキソエトキシ]メチル}グリシンアミド
13C-NMR (125MHz,DMSO-d6)δ37.4,41.9,42.2,43.6,54.2,64.5,65.6,65.7,69.1,126.3,127.77,127.85,128.10,128.14,128.2,128.4,128.5,129.2,135.8,137.0,137.9,156.6,168.9,169.5,169.9,170.2,171.5.
グリシルグリシル-L-フェニルアラニル-N-[(カルボキシメトキシ)メチル]グリシンアミド
13C-NMR (100MHz,D2O)δ37.3,41.0,42.7,43.2,56.0,67.3,70.0,127.8,129.4,129.8,136.9,168.4,171.7,172.9,174.4,178.1.
MS(ESI)(m/z):422([M-H]-).
6-(2,5-ジオキソ-2,5-ジヒドロ-1H-ピロール-1-イル)ヘキサン酸
(実施例10)
1-{6-[(2,5-ジオキソピロリジン-1-イル)オキシ]-6-オキソヘキシル}-1H-ピロール-2,5-ジオン
13C-NMR (100MHz,DMSO-d6)δ23.7,25.1,25.4,27.4,30.0,36.8,134.4,168.9,170.2,171.1.
MS(ESI)(m/z):309([M+H]+).
1-{6-[(2,5-ジオキソピロリジン-1-イル)オキシ]-6-オキソヘキシル}-1H-ピロール-2,5-ジオン
13C-NMR (100MHz,DMSO-d6)δ23.7,25.1,25.4,27.4,30.0,36.8,134.4,168.9,170.2,171.1.
MS(ESI)(m/z):309([M+H]+).
N-[6-(2,5-ジオキソ-2,5-ジヒドロ-1H-ピロール-1-イル)ヘキサノイル]グリシルグリシル-L-フェニルアラニル-N-[(カルボキシメトキシ)メチル]グリシンアミド
13C-NMR (100MHz,DMSO-d6)δ24.6,25.8,27.8,34.9,37.0,37.2,41.9,42.1,42.1,54.2,65.1,69.2,126.2,128.1,129.1,134.4,137.9,168.9,169.5,169.8,171.1,171.4,171.9,172.6.
MS(ESI)(m/z):615([M-H]-).
N-[6-(2,5-ジオキソ-2,5-ジヒドロ-1H-ピロール-1-イル)ヘキサノイル]グリシルグリシル-L-フェニルアラニル-N-[(カルボキシメトキシ)メチル]グリシンアミドの1,2-ジメトキシエタン付加物
13C-NMR (100MHz,DMSO-d6)δ25.5,26.8,28.7,35.9,37.9,38.2,42.8,43.0,43.1,55.1,59.0,65.2,69.8,72.0,127.2,129.0,130.1,135.4,138.8,169.8,170.4,170.9,172.0,172.3,172.4,173.6.
MS(ESI)(m/z):615([M-H]-).
標題化合物の結晶について、銅のKα線の照射で得られる粉末X線回折を行った。結果を表1及び図3に示す。19.0°、及び25.0°の回折角度(2θ)に主要なピークが認められた。
N-[6-(2,5-ジオキソ-2,5-ジヒドロ-1H-ピロール-1-イル)ヘキサノイル]グリシルグリシル-L-フェニルアラニル-N-[(2-{[(1S,9S)-9-エチル-5-フルオロ-9-ヒドロキシ-4-メチル-10,13-ジオキソ-2,3,9,10,13,15-ヘキサヒドロ-1H,12H-ベンゾ[de]ピラノ[3’,4’:6,7]インドリジノ[1,2-b]キノリン-1-イル]アミノ}-2-オキソエトキシ)メチル]グリシンアミド
13C-NMR (100MHz,DMSO-d6)δ7.6,10.8,10.9,23.5,24.6,25.7,27.7,30.2,30.6,34.8,36.9,37.1,41.7,42.0,44.4,49.5,54.1,65.1,66.9,69.7,72.2,96.6,109.6,109.8,119.0,121.5,123.4,123.6,125.3,126.2,128.0,129.0,134.3,136.2,136.3,137.7,140.4,145.0,147.7,147.8,149.9,152.2,156.6,160.2,162.7,168.8,169.1,169.3,170.0,171.0,171.3,172.3,172.5.
MS(ESI)(m/z):1034([M+H]+).
標題化合物の結晶について、銅のKα線の照射で得られる粉末X線回折を行った。結果を表2及び図4に示す。5.6°、15.5°、及び22.0°の回折角度(2θ)に主要なピークが認められた。
({N-[(9H-フルオレン-9-イルメトキシ)カルボニル]グリシル}アミノ)メチルアセテート
ベンジル[({N-[(9H-フルオレン-9-イルメトキシ)カルボニル]グリシル}アミノ)メトキシ]アセテート
ベンジル[({N-[(9H-フルオレン-9-イルメトキシ)カルボニル]グリシルグリシル-L-フェニルアラニル}アミノ)メトキシ]アセテート
13C-NMR (100MHz,DMSO-d6)δ37.3, 41.8, 42.1, 43.5, 46.6, 54.1, 64.4, 65.6, 65.7, 69.0, 120.1, 125.2, 126.3, 127.1, 127.6, 128.0, 128.1,128.1, 128.4, 129.1, 135.8, 137.8, 140.7, 143.8, 156.5, 168.8, 169.4, 169.9, 170.1, 171.4.
MS(ESI)(m/z):736([M+H]+).
N-[(9H-フルオレン-9-イルメトキシ)カルボニル]グリシルグリシル-L-フェニルアラニル-N-[(カルボキシメトキシ)メチル]グリシンアミド
13C-NMR (100MHz,CDCl3)δ37.4, 41.8, 42.1, 43.5, 46.6, 54.1, 64.2, 65.7, 68.8, 120.1, 125.2, 126.3, 127.1, 127.6, 128.1, 129.1, 137.8, 140.7, 143.8, 156.5, 168.8, 169.4, 170.0, 171.4, 171.4.
MS(ESI)(m/z):646([M+H]+).
N-[(9H-フルオレン-9-イルメトキシ)カルボニル]グリシルグリシル-L-フェニルアラニル-N-[(2-{[(1S,9S)-9-エチル-5-フルオロ-9-ヒドロキシ-4-メチル-10,13-ジオキソ-2,3,9,10,13,15-ヘキサヒドロ-1H,12H-ベンゾ[de]ピラノ[3‘,4’:6,7]インドリジノ[1,2-b]キノリン-1-イル]アミノ}-2-オキソエトキシ)メチル]グリシンアミド
13C-NMR(100MHz,DMSO-d6)δ7.7, 10.9, 11.0, 23.1, 23.7, 27.8, 30.3, 31.4, 37.3, 41.8, 42.1, 43.5, 44.6, 46.6, 49.6, 54.2, 55.6, 65.2, 65.8, 67.0, 69.8, 72.3, 82.0, 96.7, 109.7, 109.9, 119.1, 120.0, 121.6, 123.5, 123.7, 125.2, 125.3, 126.3, 127.0, 127.6,128.1, 129.1, 136.3, 136.4, 137.8, 140.5, 140.7, 143.8, 143.8, 145.1, 147.8, 147.9, 150.0, 152.3, 156.5, 156.7, 160.3, 162.8, 168.9, 169.2, 169.4, 170.2, 171.4, 172.4.
MS(ESI)1063:(M+H)+
グリシルグリシル-L-フェニルアラニル-N-[(2-{[(1S,9S)-9-エチル-5-フルオロ-9-ヒドロキシ-4-メチル-10,13-ジオキソ-2,3,9,10,13,15-ヘキサヒドロ-1H,12H-ベンゾ[de]ピラノ[3‘,4’:6,7]インドリジノ[1,2-b]キノリン-1-イル]アミノ}-2-オキソエトキシ)メチル]グリシンアミド
MS(ESI)841:(M+H)+
N-[6-(2,5-ジオキソ-2,5-ジヒドロ-1H-ピロール-1-イル)ヘキサノイル]グリシルグリシル-L-フェニルアラニル-N-[(2-{[(1S,9S)-9-エチル-5-フルオロ-9-ヒドロキシ-4-メチル-10,13-ジオキソ-2,3,9,10,13,15-ヘキサヒドロ-1H,12H-ベンゾ[de]ピラノ[3‘,4’:6,7]インドリジノ[1,2-b]キノリン-1-イル]アミノ}-2-オキソエトキシ)メチル]グリシンアミドの種晶の調製
N-[6-(2,5-ジオキソ-2,5-ジヒドロ-1H-ピロール-1-イル)ヘキサノイル]グリシルグリシル-L-フェニルアラニル-N-[(2-{[(1S,9S)-9-エチル-5-フルオロ-9-ヒドロキシ-4-メチル-10,13-ジオキソ-2,3,9,10,13,15-ヘキサヒドロ-1H,12H-ベンゾ[de]ピラノ[3‘,4’:6,7]インドリジノ[1,2-b]キノリン-1-イル]アミノ}-2-オキソエトキシ)メチル]グリシンアミド
N-[6-(2,5-ジオキソ-2,5-ジヒドロ-1H-ピロール-1-イル)ヘキサノイル]グリシルグリシル-L-フェニルアラニル-N-[(2-{[(1S,9S)-9-エチル-5-フルオロ-9-ヒドロキシ-4-メチル-10,13-ジオキソ-2,3,9,10,13,15-ヘキサヒドロ-1H,12H-ベンゾ[de]ピラノ[3’,4’:6,7]インドリジノ[1,2-b]キノリン-1-イル]アミノ}-2-オキソエトキシ)メチル]グリシンアミド
機器データは、実施例14に記載の化合物と同様であった。
N-[6-(2,5-ジオキソ-2,5-ジヒドロ-1H-ピロール-1-イル)ヘキサノイル]グリシルグリシル-L-フェニルアラニル-N-[(2-{[(1S,9S)-9-エチル-5-フルオロ-9-ヒドロキシ-4-メチル-10,13-ジオキソ-2,3,9,10,13,15-ヘキサヒドロ-1H,12H-ベンゾ[de]ピラノ[3’,4’:6,7]インドリジノ[1,2-b]キノリン-1-イル]アミノ}-2-オキソエトキシ)メチル]グリシンアミド
配列番号2:抗HER2抗体軽鎖のアミノ酸配列
配列番号3:抗HER3抗体の重鎖のアミノ酸配列
配列番号4:抗HER3抗体の軽鎖のアミノ酸配列
配列番号5:抗TROP2抗体重鎖のアミノ酸配列
配列番号6:抗TROP2抗体軽鎖のアミノ酸配列
配列番号7:抗B7-H3抗体重鎖のアミノ酸配列
配列番号8:抗B7-H3抗体軽鎖のアミノ酸配列
配列番号9:抗GPR20抗体重鎖のアミノ酸配列
配列番号10:抗GPR20抗体軽鎖のアミノ酸配列
Claims (52)
- 銅のKα線の照射で得られる粉末X線回折において、5.6±0.2°、15.5±0.2°、及び22.0±0.2°の回折角度(2θ)に主要なピークを示す、請求項1に記載の結晶。
- 式(1)で表される化合物の結晶が、銅のKα線の照射で得られる粉末X線回折において、5.6±0.2°、15.5±0.2°、及び22.0±0.2°の回折角度(2θ)に主要なピークを示す、請求項3に記載の製造方法。
- 式(1)で表される化合物が溶解した溶液が、低級ケトンと低級アルコールを溶媒として含む、請求項3又は4に記載の製造方法。
- 低級ケトンがアセトンである、請求項5に記載の製造方法。
- 低級ケトンがメチルエチルケトンである、請求項5に記載の製造方法。
- 低級アルコールが1-プロパノールである、請求項5から7のいずれか1項に記載の製造方法。
- 低級アルコールが2-ブタノールである、請求項5から7のいずれか1項に記載の製造方法。
- 式(1)で表される化合物の結晶の種晶を添加する工程を含む、請求項3から9のいずれか1項に記載の製造方法。
- 式(1)で表される化合物が、製造方法(I)によって製造されることを特徴とする、請求項3から10のいずれか1項に記載の製造方法;
(ここで、製造方法(I)は、
式(B)
式(8)
で表される化合物へ変換する工程、次いで、式(8)で表される化合物と、
式(C)
で表される化合物(ここで、Xは活性エステル基、又はカルボキシ基を示す)を縮合することにより、
式(10)
で表される化合物へ変換する工程、次いで、式(10)で表される化合物と、式(11)
で表される化合物を縮合することにより、
式(1)
で表される化合物へ変換する工程、を含む製造方法である)。 - 式(1)で表される化合物が、製造方法(II)によって製造されることを特徴とする、請求項3から10のいずれか1項に記載の製造方法;
(ここで、製造方法(II)は、
式(B)
式(D)
で表される化合物(ここで、R2は前記と同意義を示す)へ変換する工程、次いで、式(D)で表される化合物と、
式(C)
で表される化合物(ここで、Xは活性エステル基、又はカルボキシ基を示す)を縮合することにより、
式(E)
で表される化合物(ここで、R2は前記と同意義を示す)へ変換する工程、次いで、式(E)で表される化合物のカルボキシ基の保護基を脱保護することにより、
式(10)
で表される化合物へ変換する工程、次いで、式(10)で表される化合物と、式(11)
で表される化合物を縮合することにより、
式(1)
で表される化合物へ変換する工程、を含む製造方法である)。 - 1,2-ジメトキシエタンを含む溶媒に、式(10)で表される化合物を溶解させる工程、次いで、式(10)で表される化合物の1,2-ジメトキシエタン付加物の結晶を析出させる工程、を含む、請求項11又は12に記載の製造方法。
- 式(10)で表される化合物の1,2-ジメトキシエタン付加物の結晶が、銅のKα線の照射で得られる粉末X線回折において、19.0±0.2°、及び25.0±0.2°の回折角度(2θ)に主要なピークを示す、請求項13に記載の製造方法。
- 式(10)で表される化合物と、式(11)で表される化合物を縮合することにより、式(1)で表される化合物へ変換する工程が、硫酸ナトリウム水溶液とテトラヒドロフランの2相系中にて行われる、請求項11から14のいずれか1項に記載の製造方法。
- 式(1)で表される化合物が、製造方法(III)によって製造されることを特徴とする、請求項3から10のいずれか1項に記載の製造方法;
(ここで、製造方法(III)は、
式(B)
式(F)
で表される化合物(ここで、R1は前記と同意義を示す)へ変換する工程、次いで、式(F)で表される化合物と、
式(11)
で表される化合物を縮合することにより、
式(G)
で表される化合物(ここで、R1は前記と同意義を示す)へ変換する工程、次いで、式(G)で表される化合物のアミノ基の保護基を脱保護することにより、
式(16)
で表される化合物へ変換する工程、次いで、式(16)で表される化合物と、
式(C)
で表される化合物(ここで、Xは活性エステル基、又はカルボキシ基を示す)を縮合することにより、
式(1)
で表される化合物へ変換する工程、を含む製造方法である)。 - 式(11)で表される化合物が、メタンスルホン酸塩である、請求項11から16のいずれか1項に記載の製造方法。
- 式(11)で表される化合物が、メタンスルホン酸塩・m水和物(ここで、mは0~3個の範囲内である)である、請求項11から16のいずれか1項に記載の製造方法。
- 式(11)で表される化合物が、メタンスルホン酸塩・2水和物である、請求項11から16のいずれか1項に記載の製造方法。
- 式(B)で表される化合物が、製造方法(IV)によって製造されることを特徴とする、請求項11から19のいずれか1項に記載の製造方法;
(ここで、製造方法(IV)は、
式(H)
で表される化合物(ここで、R3は保護基で保護されたアミノ基を示す)と、四酢酸鉛と反応させることにより、
式(J)
で表される化合物(ここで、R3は前記と同意義を示す)へ変換する工程、次いで、式(J)で表される化合物と、
式(K)
で表される化合物(ここで、R2は請求項11から19のいずれか1項に記載のR2と同義を示す)を、酸又は塩基の存在下で反応させることにより、
式(L)
で表される化合物(ここで、R2及びR3は前記と同意義を示す)へ変換する工程、次いで、式(L)で表される化合物のアミノ基の保護基を脱保護することにより、
式(M)
で表される化合物(ここで、R2は前記と同意義を示す)へ変換する工程、次いで、式(M)で表される化合物と、
式(N)
式(B)
で表される化合物(ここで、R1及びR2は前記と同意義を示す)へ変換する工程、を含む製造方法である)。 - 式(H)で表される化合物を四酢酸鉛と反応させることにより式(J)で表される化合物へ変換する工程が、酢酸の存在下で行われる、請求項20に記載の製造方法。
- 式(J)で表される化合物と式(K)で表される化合物を反応させ、式(L)で表される化合物へ変換する工程が、水酸化ナトリウム水溶液の存在下で行われる、請求項20又は21に記載の製造方法。
- 式(J)で表される化合物と式(K)で表される化合物を反応させ、式(L)で表される化合物へ変換する工程が、トリス(ペンタフルオロフェニル)ボランの存在下で行われる、請求項20又は21に記載の製造方法。
- 式(L)で表される化合物のアミノ基の保護基を脱保護することにより、式(M)で表される化合物へ変換する工程の後、酸を添加することにより、式(M)で表される化合物と酸との塩を析出させる工程を含む、請求項20から23のいずれか1項に記載の製造方法。
- 酸が、1-ヒドロキシベンゾトリアゾールである、請求項24に記載の製造方法。
- R1がベンジルオキシカルボニル基で保護されたアミノ基である、請求項11から25のいずれか1項に記載の製造方法。
- R1が(9H-フルオレン-9-イルメトキシ)カルボニル基で保護されたアミノ基である、請求項11から25のいずれか1項に記載の製造方法。
- R2がベンジル基で保護されたカルボキシ基である、請求項11から27のいずれか1項に記載の製造方法。
- R3が(9H-フルオレン-9-イルメトキシ)カルボニル基で保護されたアミノ基である、請求項20から28のいずれか1項に記載の製造方法。
- Xが(2,5-ジオキソピロリジン-1-イル)オキシカルボニル基である、請求項11から29のいずれか1項に記載の製造方法。
- 式(1)で表される化合物が、製造方法(V)によって製造されることを特徴とする、請求項3から10のいずれか1項に記載の製造方法;
(ここで、製造方法(V)は、
式(2)
で表される化合物を、四酢酸鉛と反応させることにより、
式(3)
で表される化合物へ変換する工程、次いで、式(3)で表される化合物を、酸又は塩基の存在下、グリコール酸ベンジルと反応させることにより、
式(4)
で表される化合物へ変換する工程、次いで、式(4)で表される化合物のアミノ基の保護基を脱保護することにより、
式(5)
で表される化合物へ変換する工程、次いで、式(5)で表される化合物と、
式(6)
で表される化合物を縮合することにより、
式(7)
で表される化合物へ変換する工程、次いで、式(7)で表される化合物のアミノ基及びカルボキシ基の保護基を脱保護し、
式(8)
で表される化合物へ変換する工程、次いで、式(8)で表される化合物と、
式(9)
で表される化合物を縮合することにより、
式(10)
で表される化合物へ変換する工程、次いで、式(10)で表される化合物と、式(11)
で表される化合物を縮合することにより、
式(1)
で表される化合物へ変換する工程、を含む製造方法である)。 - 1,2-ジメトキシエタンを含む溶媒に、式(10)で表される化合物を溶解させる工程、次いで、式(10)で表される化合物の1,2-ジメトキシエタン付加物の結晶を析出させる工程、を含む、請求項31に記載の製造方法。
- 式(10)で表される化合物の1,2-ジメトキシエタン付加物の結晶が、銅のKα線の照射で得られる粉末X線回折において、19.0±0.2°、及び25.0±0.2°の回折角度(2θ)に主要なピークを示す、請求項32に記載の製造方法。
- 式(10)で表される化合物と、式(11)で表される化合物を縮合することにより、式(1)で表される化合物へ変換する工程が、硫酸ナトリウム水溶液とテトラヒドロフランの2相系中にて行われる、請求項31から33のいずれか1項に記載の製造方法。
- 式(1)で表される化合物が、製造方法(VI)によって製造されることを特徴とする、請求項3から10のいずれか1項に記載の製造方法;
(ここで、製造方法(VI)は、
式(2)
で表される化合物を、四酢酸鉛と反応させることにより、
式(3)
で表される化合物へ変換する工程、次いで、式(3)で表される化合物を、酸又は塩基の存在下、グリコール酸ベンジルと反応させることにより、
式(4)
で表される化合物へ変換する工程、次いで、式(4)で表される化合物のアミノ基の保護基を脱保護することにより、
式(5)
で表される化合物へ変換する工程、次いで、式(5)で表される化合物と、
式(12)
で表される化合物を縮合することにより、
式(13)
で表される化合物へ変換する工程、次いで、式(13)で表される化合物のカルボキシ基の保護基を脱保護することにより、
式(14)
で表される化合物へ変換する工程、次いで、式(14)で表される化合物と、
式(11)
で表される化合物を縮合することにより、
式(15)
で表される化合物へ変換する工程、次いで、式(15)で表される化合物のアミノ基の保護基を脱保護することにより、
式(16)
で表される化合物へ変換する工程、次いで、式(16)で表される化合物と、
式(9)
で表される化合物を縮合することにより、
式(1)
で表される化合物へ変換する工程、を含む製造方法である)。 - 式(2)で表される化合物を四酢酸鉛と反応させることにより式(3)で表される化合物へ変換する工程が、酢酸の存在下で行われる、請求項31から35のいずれか1項に記載の製造方法。
- 式(3)で表される化合物を式(4)で表される化合物へ変換する工程が、水酸化ナトリウム水溶液の存在下で行われる、請求項31から36のいずれか1項に記載の製造方法。
- 式(3)で表される化合物を式(4)で表される化合物へ変換する工程が、トリス(ペンタフルオロフェニル)ボランの存在下で行われる、請求項31から36のいずれか1項に記載の製造方法。
- 式(4)で表される化合物のアミノ基の保護基を脱保護することにより、式(5)で表される化合物へ変換する工程の後、酸を添加することにより、式(5)で表される化合物と酸との塩を析出させる工程を含む、請求項31から38のいずれか1項に記載の製造方法。
- 酸が、1-ヒドロキシベンゾトリアゾールである、請求項39に記載の製造方法。
- 式(11)で表される化合物が、メタンスルホン酸塩である、請求項31から42のいずれか1項に記載の製造方法。
- 式(11)で表される化合物が、メタンスルホン酸塩・m水和物(ここで、mは0~3個の範囲内である)である、請求項31から42のいずれか1項に記載の製造方法。
- 式(11)で表される化合物が、メタンスルホン酸塩・2水和物である、請求項31から42のいずれか1項に記載の製造方法。
- クロマトグラフィーを使用しないことを特徴とする、請求項3から45のいずれか1項に記載の製造方法。
- 銅のKα線の照射で得られる粉末X線回折において、19.0±0.2°、及び25.0±0.2°の回折角度(2θ)に主要なピークを示す、請求項47に記載の結晶。
- 酸が1-ヒドロキシベンゾトリアゾールである、請求項49に記載の塩。
- 抗体が、抗HER2抗体、抗HER3抗体、抗TROP2抗体、抗B7-H3抗体、又は抗GPR20抗体である、請求項51に記載の製造方法。
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG11202000997YA SG11202000997YA (en) | 2017-08-31 | 2018-08-30 | Improved method for producing antibody-drug conjugate |
KR1020207008823A KR20200041993A (ko) | 2017-08-31 | 2018-08-30 | 항체-약물 콘주게이트의 개량 제조 방법 |
AU2018327171A AU2018327171B2 (en) | 2017-08-31 | 2018-08-30 | Improved method for producing antibody-drug conjugate |
JP2019539605A JP7366745B2 (ja) | 2017-08-31 | 2018-08-30 | 抗体-薬物コンジュゲートの改良製造方法 |
CA3073924A CA3073924C (en) | 2017-08-31 | 2018-08-30 | Improved method for producing antibody-drug conjugate |
EP18849765.5A EP3677589A4 (en) | 2017-08-31 | 2018-08-30 | IMPROVED PROCESS FOR PREPARING ANTIBODY-ACTIVE CONJUGATE |
CN201880056466.XA CN111051330A (zh) | 2017-08-31 | 2018-08-30 | 抗体-药物缀合物的改进制备方法 |
US16/642,245 US11945882B2 (en) | 2017-08-31 | 2018-08-30 | Method for producing antibody-drug conjugate |
BR112020003646-3A BR112020003646A2 (pt) | 2017-08-31 | 2018-08-30 | cristais, métodos para produção de cristais e de um conjugado anticorpo-fármaco, e, sal. |
IL272965A IL272965A (en) | 2017-08-31 | 2020-02-27 | Improved methods of producing antibody-drug conjugates |
AU2023203615A AU2023203615A1 (en) | 2017-08-31 | 2023-06-09 | Improved method for producing antibody-drug conjugate |
JP2023109892A JP2023126890A (ja) | 2017-08-31 | 2023-07-04 | 抗体-薬物コンジュゲートの改良製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017167691 | 2017-08-31 | ||
JP2017-167691 | 2017-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019044947A1 true WO2019044947A1 (ja) | 2019-03-07 |
Family
ID=65525614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/032056 WO2019044947A1 (ja) | 2017-08-31 | 2018-08-30 | 抗体-薬物コンジュゲートの改良製造方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US11945882B2 (ja) |
EP (1) | EP3677589A4 (ja) |
JP (2) | JP7366745B2 (ja) |
KR (1) | KR20200041993A (ja) |
CN (1) | CN111051330A (ja) |
AU (2) | AU2018327171B2 (ja) |
BR (1) | BR112020003646A2 (ja) |
CA (1) | CA3073924C (ja) |
IL (1) | IL272965A (ja) |
SG (1) | SG11202000997YA (ja) |
TW (1) | TWI843705B (ja) |
WO (1) | WO2019044947A1 (ja) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020022363A1 (ja) | 2018-07-25 | 2020-01-30 | 第一三共株式会社 | 抗体-薬物コンジュゲートの効果的な製造方法 |
WO2020027100A1 (ja) | 2018-07-31 | 2020-02-06 | 第一三共株式会社 | 抗体-薬物コンジュゲート投与による転移性脳腫瘍の治療 |
WO2020031936A1 (ja) | 2018-08-06 | 2020-02-13 | 第一三共株式会社 | 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
WO2020059772A1 (ja) | 2018-09-20 | 2020-03-26 | 第一三共株式会社 | 抗her3抗体-薬物コンジュゲート投与によるher3変異がんの治療 |
WO2020122034A1 (ja) | 2018-12-11 | 2020-06-18 | 第一三共株式会社 | 抗体-薬物コンジュゲートとparp阻害剤の組み合わせ |
WO2020130125A1 (ja) | 2018-12-21 | 2020-06-25 | 第一三共株式会社 | 抗体-薬物コンジュゲートとキナーゼ阻害剤の組み合わせ |
CN111686259A (zh) * | 2019-05-26 | 2020-09-22 | 四川百利药业有限责任公司 | 一种含sn38的抗体药物偶联物 |
EP3673918A4 (en) * | 2017-08-23 | 2021-05-19 | Daiichi Sankyo Company, Limited | ANTIBODY-DRUG CONJUGATE PREPARATION AND ASSOCIATED LYOPHILIZATION |
WO2021260583A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
WO2021260582A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and aurora b inhibitor |
WO2021260578A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and cdk9 inhibitor |
WO2021260580A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atm inhibitor |
WO2021260579A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atr inhibitor |
CN113939318A (zh) * | 2019-05-29 | 2022-01-14 | 第一三共株式会社 | 抗体-药物缀合物的制剂 |
WO2022014698A1 (ja) | 2020-07-17 | 2022-01-20 | 第一三共株式会社 | 抗体-薬物コンジュゲートの製造方法 |
WO2022074617A1 (en) | 2020-10-09 | 2022-04-14 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
WO2022102695A1 (ja) | 2020-11-12 | 2022-05-19 | 第一三共株式会社 | 抗b7-h3抗体-薬物コンジュゲート投与による中皮腫の治療 |
WO2022102634A1 (ja) | 2020-11-11 | 2022-05-19 | 第一三共株式会社 | 抗体-薬物コンジュゲートと抗SIRPα抗体の組み合わせ |
WO2023089527A1 (en) | 2021-11-18 | 2023-05-25 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
WO2023126823A1 (en) | 2021-12-28 | 2023-07-06 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atr inhibitor |
WO2023126822A1 (en) | 2021-12-28 | 2023-07-06 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and rasg12c inhibitor |
WO2023175483A1 (en) | 2022-03-16 | 2023-09-21 | Astrazeneca Uk Limited | A scoring method for an anti-trop2 antibody‑drug conjugate therapy |
WO2023209591A1 (en) | 2022-04-27 | 2023-11-02 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
WO2023218378A1 (en) | 2022-05-11 | 2023-11-16 | Daiichi Sankyo Company, Limited | Combination of an antibody specific for a tumor antigen and a cd47 inhibitor |
WO2024023750A1 (en) | 2022-07-28 | 2024-02-01 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and bispecific checkpoint inhibitor |
WO2024116094A1 (en) | 2022-11-30 | 2024-06-06 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugates and dnmt inhibitors |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL268102B1 (en) * | 2017-01-17 | 2024-08-01 | Daiichi Sankyo Co Ltd | Anti-GPR 20 antibody and anti-GPR 20 antibody-drug conjugate |
CA3186295A1 (en) | 2020-06-08 | 2021-12-16 | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof |
TW202300148A (zh) * | 2021-03-17 | 2023-01-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 喜樹鹼衍生物的製備方法 |
WO2022218415A1 (zh) * | 2021-04-15 | 2022-10-20 | 江苏恒瑞医药股份有限公司 | 一种依喜替康类似物的结晶形式及其制备方法 |
CN113264983A (zh) * | 2021-05-20 | 2021-08-17 | 联宁(苏州)生物制药有限公司 | 一种用于抗体偶联药物的连接子lnd1088的合成方法 |
CN113336823A (zh) * | 2021-05-28 | 2021-09-03 | 联宁(苏州)生物制药有限公司 | 一种用于抗体偶联药物连接子lnd1067的合成方法 |
CN113402584A (zh) * | 2021-07-06 | 2021-09-17 | 联宁(苏州)生物制药有限公司 | 一种抗体偶联药物连接子的中间体lnd1067-l1的合成方法 |
CN113527418B (zh) * | 2021-07-16 | 2022-05-03 | 成都普康唯新生物科技有限公司 | 一种ADC linker的制备方法 |
EP4434548A1 (en) | 2021-11-15 | 2024-09-25 | Systimmune, Inc. | Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof |
CN118056009A (zh) | 2021-12-02 | 2024-05-17 | 岩唐生物科技(杭州)有限责任公司 | 分离的多肽及其应用 |
AU2022402061A1 (en) | 2021-12-03 | 2024-07-11 | Systimmune, Inc. | Anti-human trop2 antibody-camptothecin drug conjugate and medical use thereof |
JP2024520988A (ja) | 2022-03-25 | 2024-05-28 | バイリ-バイオ(チェンドゥ)ファーマスーティカル シーオー.,エルティーディー. | Dna毒性二量体及びその複合体 |
TW202421203A (zh) * | 2022-09-30 | 2024-06-01 | 大陸商成都百利多特生物藥業有限責任公司 | 一種帶有高穩定性親水連接單元的奧瑞他汀類藥物及其偶聯物 |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990007861A1 (en) | 1988-12-28 | 1990-07-26 | Protein Design Labs, Inc. | CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR |
JPH0680891A (ja) * | 1991-07-04 | 1994-03-22 | Mitsui Toatsu Chem Inc | フルオラン化合物の結晶性プロパノール和物およびその 製造法ならびに該結晶性プロパノール和物を含有する記 録材料 |
US5821337A (en) | 1991-06-14 | 1998-10-13 | Genentech, Inc. | Immunoglobulin variants |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
WO2000061739A1 (en) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
WO2001000245A2 (en) | 1999-06-25 | 2001-01-04 | Genentech, Inc. | HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
WO2002031140A1 (fr) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Cellules produisant des compositions d'anticorps |
WO2003038043A2 (en) | 2001-11-01 | 2003-05-08 | Uab Research Foundation | Combinations of dr5 antibody and other therapeutic agents |
JP2005343837A (ja) * | 2004-06-04 | 2005-12-15 | Fuji Photo Film Co Ltd | 1,3−ジオキソラン−4,6−ジオン化合物の製造方法 |
WO2007077028A2 (en) | 2005-12-30 | 2007-07-12 | U3 Pharma Ag | Antibodies directed to her-3 and uses thereof |
WO2008100624A2 (en) | 2007-02-16 | 2008-08-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
WO2014057687A1 (ja) | 2012-10-11 | 2014-04-17 | 第一三共株式会社 | 抗体-薬物コンジュゲート |
WO2015098099A1 (ja) | 2013-12-25 | 2015-07-02 | 第一三共株式会社 | 抗trop2抗体-薬物コンジュゲート |
WO2015115091A1 (ja) | 2014-01-31 | 2015-08-06 | 第一三共株式会社 | 抗her2抗体-薬物コンジュゲート |
WO2015155998A1 (en) | 2014-04-10 | 2015-10-15 | Daiichi Sankyo Company, Limited | Anti-her3 antibody-drug conjugate |
WO2018135501A1 (ja) | 2017-01-17 | 2018-07-26 | 第一三共株式会社 | 抗gpr20抗体及び抗gpr20抗体-薬物コンジュゲート |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
JP3008226B2 (ja) | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
US5637770A (en) | 1991-01-16 | 1997-06-10 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic compound |
JP3359955B2 (ja) | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
JPH08337584A (ja) | 1995-04-10 | 1996-12-24 | Dai Ichi Seiyaku Co Ltd | 縮合六環式アミノ化合物、これを含有する医薬及びその製法 |
US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
JPH1095802A (ja) | 1995-12-28 | 1998-04-14 | Tanabe Seiyaku Co Ltd | カンプトテシン誘導体 |
CA2192725C (en) | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
JPH1171280A (ja) | 1997-06-26 | 1999-03-16 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
JPH1192405A (ja) | 1997-09-19 | 1999-04-06 | Dai Ichi Seiyaku Co Ltd | 薬物複合体 |
US6071719A (en) | 1998-03-11 | 2000-06-06 | Smithkline Beecham Corporation | DNA encoding ECR 673: A 7-transmembrane G-protein coupled receptor |
CA2333321A1 (en) | 1998-05-22 | 1999-12-02 | Daiichi Pharmaceutical Co., Ltd. | Drug complex |
AU765409B2 (en) | 1998-10-30 | 2003-09-18 | Daiichi Pharmaceutical Co., Ltd. | DDS compounds and method for assaying the same |
WO2001000244A2 (en) | 1999-06-25 | 2001-01-04 | Genentech, Inc. | METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES |
JP2002060351A (ja) | 2000-03-22 | 2002-02-26 | Dai Ichi Seiyaku Co Ltd | 水酸基を有する薬物を含むdds化合物 |
MXPA02012791A (es) | 2000-06-29 | 2003-12-11 | Daiichi Seiyaku Co | Compuestos dds y metodo para prepararlo. |
KR20030023697A (ko) | 2000-07-13 | 2003-03-19 | 다이이찌 세이야꾸 가부시기가이샤 | Dds 화합물을 함유하는 의약 조성물 |
US20030018989A1 (en) | 2001-03-29 | 2003-01-23 | Brennan Thomas J. | Transgenic mice containing GPCR5-1 gene disruptions |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
TWI313609B (en) | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
JP2005511627A (ja) | 2001-11-20 | 2005-04-28 | シアトル ジェネティクス,インコーポレーテッド | 抗cd30抗体を使用する免疫学的疾患の治療 |
US7585491B2 (en) | 2002-12-13 | 2009-09-08 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
ES2871905T3 (es) | 2002-03-01 | 2021-11-02 | Immunomedics Inc | Inmunoconjugado que comprende anticuerpos de RS7 humanizados |
US9745380B2 (en) | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
EP1581648A2 (en) | 2002-09-09 | 2005-10-05 | Nura, Inc. | G protein coupled receptors and uses thereof |
US20080260744A1 (en) | 2002-09-09 | 2008-10-23 | Omeros Corporation | G protein coupled receptors and uses thereof |
US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
WO2005040825A2 (en) | 2003-10-24 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20) |
JP2007527872A (ja) | 2004-02-26 | 2007-10-04 | イノテック ファーマシューティカルズ コーポレイション | イソキノリン誘導体及びその使用方法 |
WO2005084390A2 (en) | 2004-03-02 | 2005-09-15 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
NZ550934A (en) | 2004-05-19 | 2010-05-28 | Medarex Inc | Chemical linkers and conjugates thereof |
AU2005249490B2 (en) | 2004-06-01 | 2010-07-29 | Genentech, Inc. | Antibody drug conjugates and methods |
KR20150043558A (ko) | 2004-07-22 | 2015-04-22 | 제넨테크, 인크. | Her2 항체 조성물 |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
JP2008521828A (ja) | 2004-11-29 | 2008-06-26 | シアトル ジェネティックス, インコーポレイテッド | 操作された抗体およびイムノコンジュゲート |
US20060135546A1 (en) * | 2004-12-16 | 2006-06-22 | Jagadevappa Basavaraja | Methods for the purification of 20(S)- camptothecin |
CN102580084B (zh) | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
DE102005009084A1 (de) | 2005-02-28 | 2006-08-31 | Ktb Tumorforschungsgesellschaft Mbh | Proteinbindende Anthrazyklin-Peptid-Derivate und diese enthaltende Arzneimittel |
DE102005009099A1 (de) | 2005-02-28 | 2006-08-31 | Ktb Tumorforschungsgesellschaft Mbh | Proteinbindende Camptothecin-Peptid-Derivate und diese enthaltende Arzneimittel |
NZ560844A (en) | 2005-03-08 | 2008-08-29 | Pharmacia & Upjohn Co Llc | Anti-MAdCAM antibody compositions |
US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
NZ599176A (en) | 2005-08-03 | 2014-04-30 | Immunogen Inc | Immunoconjugate formulations |
US20080131428A1 (en) | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
TWI523864B (zh) | 2006-05-30 | 2016-03-01 | 建南德克公司 | 抗體及免疫接合物及其用途 |
CN101490087B (zh) | 2006-05-30 | 2013-11-06 | 健泰科生物技术公司 | 抗体和免疫偶联物及其用途 |
ITMI20061473A1 (it) | 2006-07-26 | 2008-01-27 | Indena Spa | Derivati della camptotecina ad attivita antitumorale |
CN101687838A (zh) | 2006-12-21 | 2010-03-31 | 先灵公司 | 抑制ksp驱动蛋白活性的吡咯并[3,2-a]吡啶衍生物 |
WO2008116219A2 (en) | 2007-03-22 | 2008-09-25 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8h9 |
CA2686238C (en) | 2007-05-15 | 2018-09-25 | F. Hoffmann-La Roche Ag | Metabotropic glutamate receptor 7(mglur7)-binding antibody |
KR101764081B1 (ko) | 2008-04-30 | 2017-08-01 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
US8541178B2 (en) | 2008-05-13 | 2013-09-24 | Genentech, Inc. | Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry |
NZ591810A (en) | 2008-09-17 | 2012-12-21 | Chiasma Inc | Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid |
US8927694B2 (en) | 2008-11-18 | 2015-01-06 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
HRP20221259T1 (hr) | 2009-02-13 | 2022-12-09 | Immunomedics, Inc. | Imunokonjugati s intracelularnom vezom koja se može rascijepiti |
KR20120104158A (ko) | 2009-07-22 | 2012-09-20 | 엔즌 파마슈티칼스, 인코포레이티드 | 7-에틸-10-히드록시캠토테신의 다분지형 중합 컨쥬게이트와 her2 수용체 길항제를 병용하여 her2 양성 암을 치료하는 방법 |
WO2011021397A1 (ja) | 2009-08-20 | 2011-02-24 | 国立大学法人千葉大学 | コルヒチン誘導体 |
JP2013505944A (ja) | 2009-09-24 | 2013-02-21 | シアトル ジェネティックス, インコーポレイテッド | Dr5リガンド薬物結合体 |
JP5931736B2 (ja) | 2009-11-13 | 2016-06-08 | ウー3・フアルマ・ゲー・エム・ベー・ハーU3 Pharma | Her−3関連疾患を治療または予防するための物質および方法 |
ES2978177T3 (es) | 2009-12-02 | 2024-09-06 | Immunomedics Inc | Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer |
ES2661228T3 (es) | 2010-05-13 | 2018-03-28 | Indiana University Research And Technology Corporation | Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona |
CN103228673A (zh) | 2010-05-17 | 2013-07-31 | 株式会社立富泰克 | 在体内具有抗肿瘤活性的抗人trop-2 抗体 |
EP2571525A4 (en) | 2010-05-18 | 2016-04-27 | Cerulean Pharma Inc | Compositions and methods for treating autoimmune and other diseases |
WO2011155579A1 (ja) | 2010-06-10 | 2011-12-15 | 北海道公立大学法人札幌医科大学 | 抗Trop-2抗体 |
KR20130050966A (ko) | 2010-07-12 | 2013-05-16 | 씨오브이엑스 테크놀로지스 아일랜드 리미티드 | 다기능적 항체 접합체 |
WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
US20120156130A1 (en) | 2010-08-06 | 2012-06-21 | Thore Hettmann | Use of her3 binding agents in prostate treatment |
EP2638066A4 (en) | 2010-11-09 | 2015-06-03 | Medimmune Llc | ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION |
CN103313990B (zh) | 2010-11-17 | 2016-07-20 | 基因泰克公司 | 丙氨酰美登醇抗体偶联物 |
CN102786418B (zh) * | 2011-05-18 | 2016-05-18 | 中国医学科学院药物研究所 | 绿原酸晶ii型表征及制备方法与在药品和保健品中应用 |
BR112014011331A2 (pt) | 2011-11-11 | 2017-04-25 | Rinat Neuroscience Corp | anticorpos específicos para trop-2 e seus usos |
US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
WO2013087716A2 (de) | 2011-12-14 | 2013-06-20 | Bayer Pharma Aktiengesellschaft | Neue binder-wirkstoff konjugate (adcs) und ihre verwendung |
US20130280282A1 (en) | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
MX2014015205A (es) | 2012-06-14 | 2015-08-14 | Ambrx Inc | Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear. |
WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体-薬物コンジュゲート |
SI2968588T1 (sl) | 2013-03-15 | 2019-05-31 | AbbVie Deutschland GmbH & Co. KG | Formulacije konjugatov protitelo proti-EGFR zdravilo |
WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
CN105085529A (zh) * | 2014-05-15 | 2015-11-25 | 广东东阳光药业有限公司 | 依鲁替尼新晶型及其制备方法 |
US11098078B2 (en) | 2015-03-04 | 2021-08-24 | Jitsubo Co., Ltd. | Peptide synthesis method |
BR112017027690A2 (pt) * | 2015-06-29 | 2018-10-09 | Daiichi Sankyo Co Ltd | método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco |
SG11202001514XA (en) * | 2017-08-31 | 2020-03-30 | Daiichi Sankyo Co Ltd | Novel method for producing antibody-drug conjugate |
-
2018
- 2018-08-30 BR BR112020003646-3A patent/BR112020003646A2/pt unknown
- 2018-08-30 US US16/642,245 patent/US11945882B2/en active Active
- 2018-08-30 SG SG11202000997YA patent/SG11202000997YA/en unknown
- 2018-08-30 JP JP2019539605A patent/JP7366745B2/ja active Active
- 2018-08-30 KR KR1020207008823A patent/KR20200041993A/ko not_active Application Discontinuation
- 2018-08-30 AU AU2018327171A patent/AU2018327171B2/en active Active
- 2018-08-30 EP EP18849765.5A patent/EP3677589A4/en active Pending
- 2018-08-30 CA CA3073924A patent/CA3073924C/en active Active
- 2018-08-30 WO PCT/JP2018/032056 patent/WO2019044947A1/ja active Application Filing
- 2018-08-30 CN CN201880056466.XA patent/CN111051330A/zh active Pending
- 2018-08-31 TW TW107130664A patent/TWI843705B/zh active
-
2020
- 2020-02-27 IL IL272965A patent/IL272965A/en unknown
-
2023
- 2023-06-09 AU AU2023203615A patent/AU2023203615A1/en active Pending
- 2023-07-04 JP JP2023109892A patent/JP2023126890A/ja active Pending
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990007861A1 (en) | 1988-12-28 | 1990-07-26 | Protein Design Labs, Inc. | CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR |
US5821337A (en) | 1991-06-14 | 1998-10-13 | Genentech, Inc. | Immunoglobulin variants |
JPH0680891A (ja) * | 1991-07-04 | 1994-03-22 | Mitsui Toatsu Chem Inc | フルオラン化合物の結晶性プロパノール和物およびその 製造法ならびに該結晶性プロパノール和物を含有する記 録材料 |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
WO2000061739A1 (en) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
WO2001000245A2 (en) | 1999-06-25 | 2001-01-04 | Genentech, Inc. | HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
WO2002031140A1 (fr) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Cellules produisant des compositions d'anticorps |
WO2003038043A2 (en) | 2001-11-01 | 2003-05-08 | Uab Research Foundation | Combinations of dr5 antibody and other therapeutic agents |
JP2005343837A (ja) * | 2004-06-04 | 2005-12-15 | Fuji Photo Film Co Ltd | 1,3−ジオキソラン−4,6−ジオン化合物の製造方法 |
WO2007077028A2 (en) | 2005-12-30 | 2007-07-12 | U3 Pharma Ag | Antibodies directed to her-3 and uses thereof |
WO2008100624A2 (en) | 2007-02-16 | 2008-08-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
WO2014057687A1 (ja) | 2012-10-11 | 2014-04-17 | 第一三共株式会社 | 抗体-薬物コンジュゲート |
WO2015098099A1 (ja) | 2013-12-25 | 2015-07-02 | 第一三共株式会社 | 抗trop2抗体-薬物コンジュゲート |
WO2015115091A1 (ja) | 2014-01-31 | 2015-08-06 | 第一三共株式会社 | 抗her2抗体-薬物コンジュゲート |
WO2015155998A1 (en) | 2014-04-10 | 2015-10-15 | Daiichi Sankyo Company, Limited | Anti-her3 antibody-drug conjugate |
WO2018135501A1 (ja) | 2017-01-17 | 2018-07-26 | 第一三共株式会社 | 抗gpr20抗体及び抗gpr20抗体-薬物コンジュゲート |
Non-Patent Citations (25)
Title |
---|
"Monoclonal Antibodies", 1980, PLENUM PRESS, pages: 365 - 367 |
ALLEY, S. C. ET AL., CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 14, 2010, pages 529 - 537 |
ANALYTICAL BIOCHEMISTRY, vol. 360, 2007, pages 75 - 83 |
BIO TECHNIQUES, vol. 28, January 2000 (2000-01-01), pages 162 - 165 |
CARMEN, S., BRIEFINGS IN FUNCTIONAL GENOMICS AND PROTEOMICS, vol. 1, no. 2, 2002, pages 189 - 203 |
CELL DEATH AND DIFFERENTIATION, vol. 15, 2008, pages 751 - 761 |
DAMLE N. K., EXPERT OPIN. BIOL. THER., vol. 4, 2004, pages 1445 - 1452 |
DUCRY, L. ET AL., BIOCONJUGATE CHEM., vol. 21, 2010, pages 5 - 13 |
HERMANSON, G. T: "Bioconjugate Techniques", 1996, ACADEMIC PRESS |
HOWARD A. ET AL., J CLIN ONCOL, vol. 29, pages 398 - 405 |
JOURNAL OF CHROMATOGRAPHY A, vol. 705, 1995, pages 129 - 134 |
KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497 |
KUROIWA, Y., NUCL. ACIDS RES., vol. 26, 1998, pages 3447 - 3448 |
MOLECULAR BIOLOGY OF THE CELL, vol. 15, December 2004 (2004-12-01), pages 5268 - 5282 |
NATURE, vol. 321, 1986, pages 522 - 525 |
OGITANI Y. ET AL., CANCER SCIENCE, vol. 107, 2016, pages 1039 - 1046 |
OGITANI Y. ET AL., CLINICAL CANCER RESEARCH, vol. 22, no. 20, 15 October 2016 (2016-10-15), pages 5097 - 5108 |
OGITANI Y. ET AL., CLINICAL CANCER RESEARCH, vol. 22, no. 20, 2016, pages 5097 - 5108 |
PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855 |
SENTER P. D. ET AL., NATURE BIOTECHNOLOGY, vol. 30, 2012, pages 631 - 637 |
SIRIWARDENA, D., OPHTHALMOLOGY, vol. 109, no. 3, 2002, pages 427 - 431 |
TOMIZUKA, K. ET AL., NATURE GENETICS, vol. 16, 1997, pages 133 - 143 |
TOMIZUKA, K., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 - 727 |
WORMSTONE, I. M., INVESTIGATIVE OPHTHALMOLOGY VISUAL SCIENCE, vol. 43, no. 7, 2002, pages 2301 - 2308 |
YOSHIDA, H.: "Animal Cell Technology: Basic and Applied Aspects", vol. 10, 1999, KLUWER ACADEMIC PUBLISHERS, pages: 69 - 73 |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3673918A4 (en) * | 2017-08-23 | 2021-05-19 | Daiichi Sankyo Company, Limited | ANTIBODY-DRUG CONJUGATE PREPARATION AND ASSOCIATED LYOPHILIZATION |
WO2020022363A1 (ja) | 2018-07-25 | 2020-01-30 | 第一三共株式会社 | 抗体-薬物コンジュゲートの効果的な製造方法 |
WO2020027100A1 (ja) | 2018-07-31 | 2020-02-06 | 第一三共株式会社 | 抗体-薬物コンジュゲート投与による転移性脳腫瘍の治療 |
WO2020031936A1 (ja) | 2018-08-06 | 2020-02-13 | 第一三共株式会社 | 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
WO2020059772A1 (ja) | 2018-09-20 | 2020-03-26 | 第一三共株式会社 | 抗her3抗体-薬物コンジュゲート投与によるher3変異がんの治療 |
WO2020122034A1 (ja) | 2018-12-11 | 2020-06-18 | 第一三共株式会社 | 抗体-薬物コンジュゲートとparp阻害剤の組み合わせ |
WO2020130125A1 (ja) | 2018-12-21 | 2020-06-25 | 第一三共株式会社 | 抗体-薬物コンジュゲートとキナーゼ阻害剤の組み合わせ |
CN111686259B (zh) * | 2019-05-26 | 2023-08-08 | 成都百利多特生物药业有限责任公司 | 一种含sn38的抗体药物偶联物 |
CN111686259A (zh) * | 2019-05-26 | 2020-09-22 | 四川百利药业有限责任公司 | 一种含sn38的抗体药物偶联物 |
CN113939318A (zh) * | 2019-05-29 | 2022-01-14 | 第一三共株式会社 | 抗体-药物缀合物的制剂 |
WO2021260582A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and aurora b inhibitor |
WO2021260578A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and cdk9 inhibitor |
WO2021260580A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atm inhibitor |
WO2021260579A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atr inhibitor |
WO2021260583A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
WO2022014698A1 (ja) | 2020-07-17 | 2022-01-20 | 第一三共株式会社 | 抗体-薬物コンジュゲートの製造方法 |
WO2022074617A1 (en) | 2020-10-09 | 2022-04-14 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
WO2022102634A1 (ja) | 2020-11-11 | 2022-05-19 | 第一三共株式会社 | 抗体-薬物コンジュゲートと抗SIRPα抗体の組み合わせ |
WO2022102695A1 (ja) | 2020-11-12 | 2022-05-19 | 第一三共株式会社 | 抗b7-h3抗体-薬物コンジュゲート投与による中皮腫の治療 |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
WO2023089527A1 (en) | 2021-11-18 | 2023-05-25 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
WO2023126822A1 (en) | 2021-12-28 | 2023-07-06 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and rasg12c inhibitor |
WO2023126823A1 (en) | 2021-12-28 | 2023-07-06 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atr inhibitor |
WO2023175483A1 (en) | 2022-03-16 | 2023-09-21 | Astrazeneca Uk Limited | A scoring method for an anti-trop2 antibody‑drug conjugate therapy |
WO2023209591A1 (en) | 2022-04-27 | 2023-11-02 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
WO2023218378A1 (en) | 2022-05-11 | 2023-11-16 | Daiichi Sankyo Company, Limited | Combination of an antibody specific for a tumor antigen and a cd47 inhibitor |
WO2024023750A1 (en) | 2022-07-28 | 2024-02-01 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and bispecific checkpoint inhibitor |
WO2024116094A1 (en) | 2022-11-30 | 2024-06-06 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugates and dnmt inhibitors |
Also Published As
Publication number | Publication date |
---|---|
EP3677589A4 (en) | 2021-04-21 |
TWI843705B (zh) | 2024-06-01 |
IL272965A (en) | 2020-04-30 |
JPWO2019044947A1 (ja) | 2020-10-15 |
AU2018327171A1 (en) | 2020-03-26 |
JP2023126890A (ja) | 2023-09-12 |
SG11202000997YA (en) | 2020-03-30 |
AU2023203615A1 (en) | 2023-07-06 |
CA3073924C (en) | 2023-10-17 |
US20200385422A1 (en) | 2020-12-10 |
CN111051330A (zh) | 2020-04-21 |
KR20200041993A (ko) | 2020-04-22 |
AU2018327171B2 (en) | 2023-03-09 |
US11945882B2 (en) | 2024-04-02 |
CA3073924A1 (en) | 2019-03-07 |
EP3677589A1 (en) | 2020-07-08 |
JP7366745B2 (ja) | 2023-10-23 |
BR112020003646A2 (pt) | 2020-09-01 |
TW201918263A (zh) | 2019-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7366745B2 (ja) | 抗体-薬物コンジュゲートの改良製造方法 | |
JP7488389B2 (ja) | 抗体-薬物コンジュゲートの新規製造方法 | |
CA3208591A1 (en) | Anti-her2 antibody-drug conjugates and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18849765 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3073924 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2019539605 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 272965 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020003646 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2018327171 Country of ref document: AU Date of ref document: 20180830 Kind code of ref document: A Ref document number: 20207008823 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018849765 Country of ref document: EP Effective date: 20200331 |
|
ENP | Entry into the national phase |
Ref document number: 112020003646 Country of ref document: BR Kind code of ref document: A2 Effective date: 20200220 |